

Approved



Cameroon
Country Operational Plan
FY 2018



Budget Summary Reports

Summary of Planned Funding by Agency and Funding Source

Agency	Funding Source			Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
	GAP	GHP-State	GHP-USAID			
State		115,653		115,653	534,347	650,000
USAID		7,936,938	1,500,000	9,436,938	864,941	10,301,879
DOD		1,551,969		1,551,969	0	1,551,969
PC		6,623		6,623	947,667	954,290
HHS/CDC	575,119	30,179,928		30,755,047	0	30,755,047
Total	575,119	39,791,111	1,500,000	41,866,230	2,346,955	44,213,185

Summary of Planned Funding by Budget Code and Agency

Budget Code	Agency					Total
	State	DOD	HHS/CDC	PC	USAID	
CIRC		0	0	0	0	0
HBHC		418,641	2,300,612	0	1,450,983	4,170,236
HKID		0	0	6,623	1,809,776	1,816,399
HLAB		47,579	1,438,552	0	0	1,486,131
HMBL		0	0	0	0	0
HMIN		0	0	0	0	0
HTXD		86,571	0	0	76,530	163,101
HTXS		453,441	16,462,161	0	707,395	17,622,997
HVAB		0	0	0	0	0
HVCT		142,586	2,209,541	0	1,266,682	3,618,809
HVMS	97,227	88,500	3,307,372	0	1,084,422	4,577,521
HVOP		160,116	0	0	1,315,547	1,475,663
HVSI	18,426	44,100	1,025,564	0	89,960	1,178,050

Approved



HVTB		22,500	488,394	0	0	510,894
IDUP		0	0	0	0	0
MTCT		37,107	1,014,152	0	0	1,051,259
OHSS		4,500	80,554	0	1,207,021	1,292,075
PDCS		24,514	680,571	0	410,196	1,115,281
PDTX		21,814	1,747,574	0	18,426	1,787,814
	115,653	1,551,969	30,755,047	6,623	9,436,938	41,866,230



Technical Areas

Technical Area Summary

Technical Area: Care

Budget Code	Budget Code Planned Amount
HBHC	4,124,247
HKID	1,781,220
HVTB	453,871
PDCS	1,092,516
Total Technical Area Planned Funding:	7,451,854

Technical Area: Governance and Systems

Budget Code	Budget Code Planned Amount
HLAB	1,274,492
HVSI	642,786
OHSS	1,128,415
Total Technical Area Planned Funding:	3,045,693

Technical Area: Prevention

Budget Code	Budget Code Planned Amount
CIRC	0
HMBL	0
HMIN	0
HVAB	0
HVCT	3,561,576
HVOP	1,398,231
IDUP	0
MTCT	1,041,359
Total Technical Area Planned Funding:	6,001,166

Approved



Technical Area: Treatment

Budget Code	Budget Code Planned Amount
HTXD	136,747
HTXS	16,952,150
PDTX	1,626,795
Total Technical Area Planned Funding:	18,715,692



Technical Area Summary Indicators and Targets

Indicator Number	Label	2019
PMTCT_STAT_DSD	PMTCT_STAT_DSD Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (DSD)	96 %
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	51,919
	Number of new ANC and L&D clients	54,184
	By Age (Denominator): 10-14	517
	By Age (Denominator): <15-19	5,986
	By Age (Denominator): 20-24	14,089
	By Number of known positives: 15-19	61
	By Number of known positives: 20-24	224
	By Number of new positives: 15-19	92
	By Number of new positives: 20-24	198
	By Number of new negative: <10	473
	By Number of new negative: 10-14	473
	By Number of new negative: 15-19	5,382
	By Number of new negative: 20-24	13,281
	By Age (Numerator): <10	473
	By Age (Numerator): 10-14	473
	By Age (Numerator): 15-19	5,550
	By Age (Numerator): 20-24	13,718
PMTCT_STAT_D_DSD_Age_Sex		18,892



	25-29, Female	
	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	9,288
	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	4,357
	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	1,055
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 25-29, Female, Known at Entry Positive	506
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 25-29, Female, Newly Identified Negative	16,625
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 25-29, Female, Newly Identified Positive	436
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 30-34, Female, Known at Entry Positive	440
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 30-34, Female, Newly Identified Negative	8,423
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 30-34, Female, Newly Identified Positive	253
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 35-39, Female, Known at Entry Positive	265
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 35-39, Female, Newly Identified Negative	3,477
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 35-39, Female, Newly Identified Positive	144
	PMTCT_STAT_N_DSD_Age_Sex_	79



	KnownNewResult 40-49, Female, Known at Entry Positive	
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 40-49, Female, Newly Identified Negative	944
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 40-49, Female, Newly Identified Positive	23
	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	17,635
	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	9,123
	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	3,895
	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	1,051
PMTCT_STAT_TA	PMTCT_STAT_TA Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (TA)	95 %
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	117,169
	Number of new ANC and L&D clients	123,834
	By Age (Denominator): 10-14	831
	By Age (Denominator): 15-19	14,634
	By Age (Denominator): 20-24	33,467
	By known positives: 15-19	57
	By known positives: 20-24	364
	By new positives: 10-14	2
	By new positives: 15-19	253



	By new positives: 20-24	633
	By new negatives: <10	678
	By new negatives: 10-14	736
	By new negatives: 15-19	13,303
	By new negatives: 20-24	30,989
	By Age (Numerator): <10	678
	By Age (Numerator): 10-14	742
	By Age (Numerator): : 15-19	13,678
	By Age (Numerator): 20-24	32,050
	PMTCT_STAT_D_TA_Age_Sex 25-29, Female	40,528
	PMTCT_STAT_D_TA_Age_Sex 30-34, Female	22,251
	PMTCT_STAT_D_TA_Age_Sex 35-39, Female	9,830
	PMTCT_STAT_D_TA_Age_Sex 40-49, Female	2,293
	PMTCT_STAT_N_TA_Age_Sex_K nownNewResult 25-29, Female, Known at Entry Positive	904
	PMTCT_STAT_N_TA_Age_Sex_K nownNewResult 25-29, Female, Newly Identified Negative	35,541
	PMTCT_STAT_N_TA_Age_Sex_K nownNewResult 25-29, Female, Newly Identified Positive	1,075
	PMTCT_STAT_N_TA_Age_Sex_K nownNewResult 30-34, Female, Known at Entry Positive	915
	PMTCT_STAT_N_TA_Age_Sex_K nownNewResult 30-34, Female, Newly Identified Negative	19,576
	PMTCT_STAT_N_TA_Age_Sex_K nownNewResult 30-34, Female,	773



	Newly Identified Positive	
	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	680
	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	7,705
	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	361
	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	81
	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	2,002
	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	64
	PMTCT_STAT_N_TA_Age_Sex 25-29, Female	37,692
	PMTCT_STAT_N_TA_Age_Sex 30-34, Female	21,326
	PMTCT_STAT_N_TA_Age_Sex 35-39, Female	8,805
	PMTCT_STAT_N_TA_Age_Sex 40-49, Female	2,198
PMTCT_ART_DSD	PMTCT_ART_DSD Percentage of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	5 %
	Number of HIV-positive pregnant women who received ART to reduce risk of	2,549



	mother-to-child-transmission (MTCT) during pregnancy	
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	51,919
	New on ART	1,155
	Already on ART at beginning of current pregnancy	1,394
PMTCT_ART_TA	PMTCT_ART_TA Percentage of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	5 %
	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	5,980
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	117,169
	New on ART	3,027
	Already on ART at beginning of current pregnancy	2,953
PrEP_NEW_DSD	PrEP_NEW_DSD Number of individuals who have received antiretroviral pre-exposure prophylaxis (PrEP) to prevent HIV infection in the reporting period.	n/a
	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting	2,077



	period to prevent HIV infection	
	Male 15-19	92
	Male 20-24	145
	Male 50+	42
	Female 15-19	116
	Female 20-24	166
	Female 50+	62
	FSW	1,158
	MSM	919
	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	241
	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	175
	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	241
	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	175
	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	166
	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	145
	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	166
	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Male	145
PP_PREV_DSD	PP_PREV_DSD Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (DSD)	n/a
	Number of the target population who completed a standardized HIV prevention intervention including	6,501



	the minimum components during the reporting period.	
	Age/sex: 10-14 Male	13
	Age/sex: 15-19 Male	65
	Age/sex: 20-24 Male	774
	Age/sex: 50+ Male	564
	Age/sex: 10-14 Female	260
	Age/sex: 15-19 Female	650
	Age/sex: 20-24 Female	650
	Age/sex: 50+ Female	65
	PP_PREV_N_DSD_Age_Sex_v2 25-29, Female	330
	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	1,245
	PP_PREV_N_DSD_Age_Sex_v2 30-34, Female	130
	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	650
	PP_PREV_N_DSD_Age_Sex_v2 35-39, Female	130
	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	520
	PP_PREV_N_DSD_Age_Sex_v2 40-49, Female	130
	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	325
PP_PREV_TA	PP_PREV_TA Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (TA-only)	n/a
	Number of the target population who completed a standardized HIV	17,733



	prevention intervention including the minimum components during the reporting period.	
	Age/sex: 10-14 Male	1,373
	Age/sex: 15-19 Male	1,482
	Age/sex: 20-24 Male	1,816
	Age/sex: 50+ Male	710
	Age/sex: 10-14 Female	2,246
	Age/sex: 15-19 Female	2,748
	Age/sex: 20-24 Female	1,983
	Age/sex: 50+ Female	889
	PP_PREV_N_TA_Age_Sex_v2 25-29, Female	618
	PP_PREV_N_TA_Age_Sex_v2 25-29, Male	504
	PP_PREV_N_TA_Age_Sex_v2 30-34, Female	617
	PP_PREV_N_TA_Age_Sex_v2 30-34, Male	504
	PP_PREV_N_TA_Age_Sex_v2 35-39, Female	617
	PP_PREV_N_TA_Age_Sex_v2 35-39, Male	504
	PP_PREV_N_TA_Age_Sex_v2 40-49, Female	617
	PP_PREV_N_TA_Age_Sex_v2 40-49, Male	504
KP_PREV_DSD	KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (DSD)	n/a
	Number of key populations reached	29,320



	with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	
	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	9,773
	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	19,547
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	674,970
	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	1,921
	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	11
	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	2,052
	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	13
	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	4,061



Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	273
Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	1,631
Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	99
Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	7,179
Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	504
Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	3,106
Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	199
Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	2,340
Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	146
Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	4,565
Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	309
Service Delivery Point (Facility) Inpatient: <1, Negative	506
Service Delivery Point (Facility) Inpatient: <1, Positive	3
Service Delivery Point (Facility) Inpatient: 1-9, Negative	1,533
Service Delivery Point (Facility) Inpatient: 1-9, Positive	9
Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	11,897
Service Delivery Point (Facility)	58



	Other PITC: 10-14, Female, Positive	
	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	12,701
	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	60
	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	18,176
	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	1,276
	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	7,329
	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	507
	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	32,119
	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	2,268
	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	13,944
	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	975
	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	10,487
	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	729
	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	20,447
	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	1,444



	Service Delivery Point (Facility) Other PITC: <1, Negative	3,115
	Service Delivery Point (Facility) Other PITC: <1, Positive	8
	Service Delivery Point (Facility) Other PITC: 1-9, Negative	9,586
	Service Delivery Point (Facility) Other PITC: 1-9, Positive	43
	Service Delivery Point (Facility) Pediatric : <5 Negative	7,952
	Service Delivery Point (Facility) Pediatric : <5 Positive	109
	Service Delivery Point (Facility) TB: 10-14, Female, Negative	47
	Service Delivery Point (Facility) TB: 10-14, Female, Positive	9
	Service Delivery Point (Facility) TB: 10-14, Male, Negative	56
	Service Delivery Point (Facility) TB: 10-14, Male, Positive	10
	Service Delivery Point (Facility) TB: 15-19, Female, Negative	53
	Service Delivery Point (Facility) TB: 15-19, Female, Positive	13
	Service Delivery Point (Facility) TB: 15-19, Male, Negative	25
	Service Delivery Point (Facility) TB: 15-19, Male, Positive	3
	Service Delivery Point (Facility) TB: 20-24, Female, Negative	195
	Service Delivery Point (Facility) TB: 20-24, Female, Positive	44
	Service Delivery Point (Facility) TB: 20-24, Male, Negative	59



	Service Delivery Point (Facility) TB: 20-24, Male, Positive	6
	Service Delivery Point (Facility) TB: 50+, Female, Negative	56
	Service Delivery Point (Facility) TB: 50+, Female, Positive	15
	Service Delivery Point (Facility) TB: 50+, Male, Negative	98
	Service Delivery Point (Facility) TB: 50+, Male, Positive	9
	Service Delivery Point (Facility) TB: <1, Negative	7
	Service Delivery Point (Facility) TB: 1-9, Negative	32
	Service Delivery Point (Facility) TB: 1-9, Positive	5
	Service Delivery Point (Facility) Index: 10-14, Female, Negative	573
	Service Delivery Point (Facility) Index: 10-14, Female, Positive	5
	Service Delivery Point (Facility) Index: 10-14, Male, Negative	607
	Service Delivery Point (Facility) Index: 10-14, Male, Positive	7
	Service Delivery Point (Facility) Index: 15-19, Female, Negative	553
	Service Delivery Point (Facility) Index: 15-19, Female, Positive	110
	Service Delivery Point (Facility) Index: 15-19, Male, Negative	241
	Service Delivery Point (Facility) Index: 15-19, Male, Positive	25
	Service Delivery Point (Facility) Index: 20-24, Female, Negative	1,082



Service Delivery Point (Facility) Index: 20-24, Female, Positive	217
Service Delivery Point (Facility) Index: 20-24, Male, Negative	511
Service Delivery Point (Facility) Index: 20-24, Male, Positive	84
Service Delivery Point (Facility) Index: 50+, Female, Negative	343
Service Delivery Point (Facility) Index: 50+, Female, Positive	54
Service Delivery Point (Facility) Index: 50+, Male, Negative	768
Service Delivery Point (Facility) Index: 50+, Male, Positive	142
Service Delivery Point (Facility) Index: <1, Negative	145
Service Delivery Point (Facility) Index: 1-9, Negative	455
Service Delivery Point (Facility) Index: 1-9, Positive	4
Service Delivery Point (Facility) ANC: 10-14, Negative	97
Service Delivery Point (Facility) ANC: 15-19, Negative	11,692
Service Delivery Point (Facility) ANC: 15-19, Positive	334
Service Delivery Point (Facility) ANC: 20-24, Negative	11,682
Service Delivery Point (Facility) ANC: 20-24, Positive	734
Service Delivery Point (Facility) VCT: 10-14, Female, Negative	4,710
Service Delivery Point (Facility) VCT: 10-14, Female, Positive	22



	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	5,024
	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	25
	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	1,511
	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	81
	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	575
	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	11
	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	2,690
	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	152
	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	1,172
	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	40
	Service Delivery Point (Facility) VCT: 50+, Female, Negative	882
	Service Delivery Point (Facility) VCT: 50+, Female, Positive	35
	Service Delivery Point (Facility) VCT: 50+, Male, Negative	1,703
	Service Delivery Point (Facility) VCT: 50+, Male, Positive	73
	Service Delivery Point (Facility) VCT: <1, Negative	1,193
	Service Delivery Point (Facility) VCT: <1, Positive	6
	Service Delivery Point (Facility) VCT: 1-9, Negative	3,786



	Service Delivery Point (Facility) VCT: 1-9, Positive	19
	HTS_TST_N_TA_EW_Age_Sex_R esult 10-14, Female, Negative	80
	HTS_TST_N_TA_EW_Age_Sex_R esult 10-14, Male, Negative	84
	HTS_TST_N_TA_EW_Age_Sex_R esult 15-19, Female, Negative	57
	HTS_TST_N_TA_EW_Age_Sex_R esult 15-19, Male, Negative	16
	HTS_TST_N_TA_EW_Age_Sex_R esult 1-9, Unknown Sex, Negative	67
	HTS_TST_N_TA_EW_Age_Sex_R esult <1, Unknown Sex, Negative	17
	HTS_TST_N_TA_EW_Age_Sex_R esult 20-24, Female, Negative	102
	HTS_TST_N_TA_EW_Age_Sex_R esult 20-24, Male, Negative	34
	HTS_TST_N_TA_EW_Age_Sex_R esult 25-29, Female, Negative	132
	HTS_TST_N_TA_EW_Age_Sex_R esult 25-29, Male, Negative	54
	HTS_TST_N_TA_EW_Age_Sex_R esult 30-34, Female, Negative	109
	HTS_TST_N_TA_EW_Age_Sex_R esult 30-34, Male, Negative	63
	HTS_TST_N_TA_EW_Age_Sex_R esult 35-39, Female, Negative	76
	HTS_TST_N_TA_EW_Age_Sex_R esult 35-39, Male, Negative	57
	HTS_TST_N_TA_EW_Age_Sex_R esult 40-49, Female, Negative	44
	HTS_TST_N_TA_EW_Age_Sex_R esult 40-49, Male, Negative	44



	HTS_TST_N_TA_EW_Age_Sex_Result 50+, Female, Negative	12
	HTS_TST_N_TA_EW_Age_Sex_Result 50+, Male, Negative	44
	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Female, Negative	1,366
	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Female, Positive	313
	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Male, Negative	815
	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Male, Positive	137
	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Female, Negative	1,526
	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Female, Positive	315
	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Male, Negative	877
	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Male, Positive	284
	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Female, Negative	1,215
	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Female, Positive	241
	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Male, Negative	878
	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Male, Positive	190
	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Female, Negative	738
	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Female, Positive	204
	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Male, Negative	889



HTS_TST_N_TA_Index_Age_Sex_ Result 40-49, Male, Positive	171
HTS_TST_N_TA_Inpat_Age_Sex_ Result 25-29, Female, Negative	9,758
HTS_TST_N_TA_Inpat_Age_Sex_ Result 25-29, Female, Positive	706
HTS_TST_N_TA_Inpat_Age_Sex_ Result 25-29, Male, Negative	5,226
HTS_TST_N_TA_Inpat_Age_Sex_ Result 25-29, Male, Positive	360
HTS_TST_N_TA_Inpat_Age_Sex_ Result 30-34, Female, Negative	10,836
HTS_TST_N_TA_Inpat_Age_Sex_ Result 30-34, Female, Positive	780
HTS_TST_N_TA_Inpat_Age_Sex_ Result 30-34, Male, Negative	6,548
HTS_TST_N_TA_Inpat_Age_Sex_ Result 30-34, Male, Positive	467
HTS_TST_N_TA_Inpat_Age_Sex_ Result 35-39, Female, Negative	8,290
HTS_TST_N_TA_Inpat_Age_Sex_ Result 35-39, Female, Positive	593
HTS_TST_N_TA_Inpat_Age_Sex_ Result 35-39, Male, Negative	5,953
HTS_TST_N_TA_Inpat_Age_Sex_ Result 35-39, Male, Positive	417
HTS_TST_N_TA_Inpat_Age_Sex_ Result 40-49, Female, Negative	4,966
HTS_TST_N_TA_Inpat_Age_Sex_ Result 40-49, Female, Positive	342
HTS_TST_N_TA_Inpat_Age_Sex_ Result 40-49, Male, Negative	5,012
HTS_TST_N_TA_Inpat_Age_Sex_ Result 40-49, Male, Positive	346



HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Female, Negative	43,689
HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Female, Positive	3,084
HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Male, Negative	23,369
HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Male, Positive	1,655
HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Female, Negative	48,546
HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Female, Positive	3,419
HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Male, Negative	29,316
HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Male, Positive	2,075
HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Female, Negative	37,117
HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Female, Positive	2,617
HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Male, Negative	26,695
HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Male, Positive	1,878
HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Female, Negative	22,243
HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Female, Positive	1,568
HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Male, Negative	22,454
HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Male, Positive	1,578
HTS_TST_N_TA_PMTCT_Age_Sex_Result 25-29, Female, Negative	25,226



HTS_TST_N_TA_PMTCT_Age_Sex_Result 25-29, Female, Positive	730
HTS_TST_N_TA_PMTCT_Age_Sex_Result 30-34, Female, Negative	16,420
HTS_TST_N_TA_PMTCT_Age_Sex_Result 30-34, Female, Positive	487
HTS_TST_N_TA_PMTCT_Age_Sex_Result 35-39, Female, Negative	5,982
HTS_TST_N_TA_PMTCT_Age_Sex_Result 35-39, Female, Positive	170
HTS_TST_N_TA_PMTCT_Age_Sex_Result 40-49, Female, Negative	1,224
HTS_TST_N_TA_PMTCT_Age_Sex_Result 40-49, Female, Positive	8
HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Female, Negative	293
HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Female, Positive	68
HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Male, Negative	138
HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Male, Positive	42
HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Female, Negative	337
HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Female, Positive	82
HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Male, Negative	167
HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Male, Positive	39
HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Female, Negative	250
HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Female, Positive	59



HTS_TST_N_TA_TBC_Age_Sex_	165
Result 35-39, Male, Negative	
HTS_TST_N_TA_TBC_Age_Sex_	37
Result 35-39, Male, Positive	
HTS_TST_N_TA_TBC_Age_Sex_	133
Result 40-49, Female, Negative	
HTS_TST_N_TA_TBC_Age_Sex_	28
Result 40-49, Female, Positive	
HTS_TST_N_TA_TBC_Age_Sex_	122
Result 40-49, Male, Negative	
HTS_TST_N_TA_TBC_Age_Sex_	35
Result 40-49, Male, Positive	
HTS_TST_N_TA_VCT_Age_Sex_	3,652
Result 25-29, Female, Negative	
HTS_TST_N_TA_VCT_Age_Sex_	186
Result 25-29, Female, Positive	
HTS_TST_N_TA_VCT_Age_Sex_	1,982
Result 25-29, Male, Negative	
HTS_TST_N_TA_VCT_Age_Sex_	88
Result 25-29, Male, Positive	
HTS_TST_N_TA_VCT_Age_Sex_	4,051
Result 30-34, Female, Negative	
HTS_TST_N_TA_VCT_Age_Sex_	213
Result 30-34, Female, Positive	
HTS_TST_N_TA_VCT_Age_Sex_	2,475
Result 30-34, Male, Negative	
HTS_TST_N_TA_VCT_Age_Sex_	108
Result 30-34, Male, Positive	
HTS_TST_N_TA_VCT_Age_Sex_	3,122
Result 35-39, Female, Negative	
HTS_TST_N_TA_VCT_Age_Sex_	140
Result 35-39, Female, Positive	
HTS_TST_N_TA_VCT_Age_Sex_	2,229
Result 35-39, Male, Negative	



	HTS_TST_N_TA_VCT_Age_Sex_ Result 35-39, Male, Positive	104
	HTS_TST_N_TA_VCT_Age_Sex_ Result 40-49, Female, Negative	1,849
	HTS_TST_N_TA_VCT_Age_Sex_ Result 40-49, Female, Positive	87
	HTS_TST_N_TA_VCT_Age_Sex_ Result 40-49, Male, Negative	1,868
	HTS_TST_N_TA_VCT_Age_Sex_ Result 40-49, Male, Positive	76
TB_STAT_DSD	TB_STAT_DSD Percentage of registered new and relapsed TB cases with documented HIV status.	99 %
	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	5,990
	Total number of registered new and relapsed TB cases, during the reporting period.	6,062
	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	186
	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	3,122
	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with	167



	documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2,515
	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	204
	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	3,174
	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	168
	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	2,516
TB_STAT_TA	TB_STAT_TA Percentage of registered new and relapsed TB cases with documented HIV status.	99 %
	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	5,736
	Total number of registered new and relapsed TB cases, during the reporting period.	5,782



	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	99
	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	103
	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	2,699
	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	2,881
	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	132
	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	3,268
	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	102
	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2,234



HTS_SELF_DSD	HTS_SELF_N_DSD	28,061
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 10-14, Female, Directly-Assisted	518
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 10-14, Female, Unassisted	518
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 10-14, Male, Directly-Assisted	518
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 10-14, Male, Unassisted	518
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 15-19, Female, Directly-Assisted	559
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 15-19, Female, Unassisted	843
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 15-19, Male, Directly-Assisted	619
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 15-19, Male, Unassisted	883
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 20-24, Male, Directly-Assisted	2,754
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 20-24, Male, Unassisted	2,507
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 25-29, Female, Directly-Assisted	2,487
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 25-29, Male, Directly-Assisted	2,459
	HTS_SELF_N_DSD_Age_Sex_HI	2,503



	VSelfTest 25-29, Male, Unassisted	
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 30-34, Male, Directly-Assisted	560
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 30-34, Male, Unassisted	2,240
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 35-39, Male, Directly-Assisted	558
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 35-39, Male, Unassisted	2,242
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 40-49, Male, Directly-Assisted	557
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 40-49, Male, Unassisted	1,984
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 50+, Male, Directly-Assisted	297
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 50+, Male, Unassisted	1,685
	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	12,067
	HTS_SELF_N_DSD_HIVSelfTest Unassisted	15,994
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	586,266
	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	6,515
	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	21
	Service Delivery Point (Facility)	6,960



	Inpatient: 10-14, Male, Negative	
	Service Delivery Point (Facility)	22
	Inpatient: 10-14, Male, Positive	
	Service Delivery Point (Facility)	1,929
	Inpatient: 15-19, Female, Negative	
	Service Delivery Point (Facility)	104
	Inpatient: 15-19, Female, Positive	
	Service Delivery Point (Facility)	846
	Inpatient: 15-19, Male, Negative	
	Service Delivery Point (Facility)	52
	Inpatient: 15-19, Male, Positive	
	Service Delivery Point (Facility)	3,281
	Inpatient: 20-24, Female, Negative	
	Service Delivery Point (Facility)	168
	Inpatient: 20-24, Female, Positive	
	Service Delivery Point (Facility)	1,493
	Inpatient: 20-24, Male, Negative	
	Service Delivery Point (Facility)	107
	Inpatient: 20-24, Male, Positive	
	Service Delivery Point (Facility)	1,196
	Inpatient: 50+, Female, Negative	
	Service Delivery Point (Facility)	79
	Inpatient: 50+, Female, Positive	
	Service Delivery Point (Facility)	2,234
	Inpatient: 50+, Male, Negative	
	Service Delivery Point (Facility)	120
	Inpatient: 50+, Male, Positive	
	Service Delivery Point (Facility)	1,710
	Inpatient: <1, Negative	
	Service Delivery Point (Facility)	4
	Inpatient: <1, Positive	
	Service Delivery Point (Facility)	5,267
	Inpatient: 1-9, Negative	
	Service Delivery Point (Facility)	19



	Inpatient: 1-9, Positive	
	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	771
	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	44
	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	629
	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	28
	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	1,600
	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	90
	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	1,253
	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	67
	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	276
	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	11
	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	890
	Service Delivery Point (Community)	45



	Mobile Testing: 50+, Male, Positive	
	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	33,702
	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	139
	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	34,856
	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	152
	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	5,814
	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	345
	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	2,892
	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	146
	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	10,092
	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	628
	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	4,899
	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	289
	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	3,412
	Service Delivery Point (Facility)	241



	Other PITC: 50+, Female, Positive	
	Service Delivery Point (Facility)	6,583
	Other PITC: 50+, Male, Negative	
	Service Delivery Point (Facility)	411
	Other PITC: 50+, Male, Positive	
	Service Delivery Point (Facility)	8,953
	Other PITC: <1, Negative	
	Service Delivery Point (Facility)	43
	Other PITC: <1, Positive	
	Service Delivery Point (Facility)	27,255
	Other PITC: 1-9, Negative	
	Service Delivery Point (Facility)	130
	Other PITC: 1-9, Positive	
	Service Delivery Point (Community)	1,284
	Other: 15-19, Female, Negative	
	Service Delivery Point (Community)	38
	Other: 15-19, Female, Positive	
	Service Delivery Point (Community)	520
	Other: 15-19, Male, Negative	
	Service Delivery Point (Community)	16
	Other: 15-19, Male, Positive	
	Service Delivery Point (Community)	2,266
	Other: 20-24, Female, Negative	
	Service Delivery Point (Community)	72
	Other: 20-24, Female, Positive	
	Service Delivery Point (Community)	982
	Other: 20-24, Male, Negative	
	Service Delivery Point (Community)	30
	Other: 20-24, Male, Positive	
	Service Delivery Point (Community)	738
	Other: 50+, Female, Negative	
	Service Delivery Point (Community)	22
	Other: 50+, Female, Positive	
	Service Delivery Point (Community)	1,444



	Other: 50+, Male, Negative	
	Service Delivery Point (Community)	44
	Other: 50+, Male, Positive	
	Service Delivery Point (Facility)	11,133
	Pediatric : <5 Negative	
	Service Delivery Point (Facility)	77
	Pediatric : <5 Positive	
	Service Delivery Point (Facility) TB: 10-14, Female, Negative	223
	Service Delivery Point (Facility) TB: 10-14, Female, Positive	43
	Service Delivery Point (Facility) TB: 10-14, Male, Negative	239
	Service Delivery Point (Facility) TB: 10-14, Male, Positive	46
	Service Delivery Point (Facility) TB: 15-19, Female, Negative	266
	Service Delivery Point (Facility) TB: 15-19, Female, Positive	50
	Service Delivery Point (Facility) TB: 15-19, Male, Negative	96
	Service Delivery Point (Facility) TB: 15-19, Male, Positive	17
	Service Delivery Point (Facility) TB: 20-24, Female, Negative	355
	Service Delivery Point (Facility) TB: 20-24, Female, Positive	72
	Service Delivery Point (Facility) TB: 20-24, Male, Negative	201
	Service Delivery Point (Facility) TB: 20-24, Male, Positive	44
	Service Delivery Point (Facility) TB: 50+, Female, Negative	127
	Service Delivery Point (Facility) TB:	17



	50+, Female, Positive	
	Service Delivery Point (Facility) TB: 50+, Male, Negative	270
	Service Delivery Point (Facility) TB: 50+, Male, Positive	70
	Service Delivery Point (Facility) TB: <1, Negative	52
	Service Delivery Point (Facility) TB: <1, Positive	10
	Service Delivery Point (Facility) TB: 1-9, Negative	179
	Service Delivery Point (Facility) TB: 1-9, Positive	35
	Service Delivery Point (Facility) Index: 10-14, Female, Negative	8,040
	Service Delivery Point (Facility) Index: 10-14, Female, Positive	141
	Service Delivery Point (Facility) Index: 10-14, Male, Negative	8,461
	Service Delivery Point (Facility) Index: 10-14, Male, Positive	153
	Service Delivery Point (Facility) Index: 15-19, Female, Negative	1,911
	Service Delivery Point (Facility) Index: 15-19, Female, Positive	423
	Service Delivery Point (Facility) Index: 15-19, Male, Negative	818
	Service Delivery Point (Facility) Index: 15-19, Male, Positive	172
	Service Delivery Point (Facility) Index: 20-24, Female, Negative	3,436
	Service Delivery Point (Facility) Index: 20-24, Female, Positive	730
	Service Delivery Point (Facility)	1,585



	Index: 20-24, Male, Negative	
	Service Delivery Point (Facility)	326
	Index: 20-24, Male, Positive	
	Service Delivery Point (Facility)	1,179
	Index: 50+, Female, Negative	
	Service Delivery Point (Facility)	241
	Index: 50+, Female, Positive	
	Service Delivery Point (Facility)	2,409
	Index: 50+, Male, Negative	
	Service Delivery Point (Facility)	497
	Index: 50+, Male, Positive	
	Service Delivery Point (Facility)	2,103
	Index: <1, Negative	
	Service Delivery Point (Facility)	39
	Index: <1, Positive	
	Service Delivery Point (Facility)	6,826
	Index: 1-9, Negative	
	Service Delivery Point (Facility)	176
	Index: 1-9, Positive	
	By Key Population: FSW, Negative	7,553
	By Key Population: FSW, Positive	1,033
	By Key Population: MSM, Negative	4,098
	By Key Population: MSM, Positive	511
	Service Delivery Point (Community)	
	Index Mod: 10-14, Female, Negative	32
	Service Delivery Point (Community)	
	Index Mod: 10-14, Male, Negative	48
	Service Delivery Point (Community)	
	Index Mod: 15-19, Female, Negative	116
	Service Delivery Point (Community)	
	Index Mod: 15-19, Female, Positive	23
	Service Delivery Point (Community)	97



	Index Mod: 15-19, Male, Negative	
	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	12
	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	258
	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	38
	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	199
	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	28
	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	48
	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	2
	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	162
	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	22
	Service Delivery Point (Facility) ANC: 10-14, Negative	149
	Service Delivery Point (Facility) ANC: 10-14, Positive	2
	Service Delivery Point (Facility) ANC: 15-19, Negative	8,266
	Service Delivery Point (Facility) ANC: 15-19, Positive	203
	Service Delivery Point (Facility) ANC: 20-24, Negative	31,984
	Service Delivery Point (Facility) ANC: 20-24, Positive	437
	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	11,402



	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	90
	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	12,172
	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	93
	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	903
	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	51
	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	493
	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	34
	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	1,603
	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	84
	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	772
	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	55
	Service Delivery Point (Facility) VCT: 50+, Female, Negative	646
	Service Delivery Point (Facility) VCT: 50+, Female, Positive	33
	Service Delivery Point (Facility) VCT: 50+, Male, Negative	1,293
	Service Delivery Point (Facility) VCT: 50+, Male, Positive	68
	Service Delivery Point (Facility) VCT: <1, Negative	3,062
	Service Delivery Point (Facility) VCT: <1, Positive	21



	Service Delivery Point (Facility) VCT: 1-9, Negative	9,210
	Service Delivery Point (Facility) VCT: 1-9, Positive	70
	Service Delivery Point (Community) VCT Mod: 10-14, Female, Negative	290
	Service Delivery Point (Community) VCT Mod: 10-14, Female, Positive	7
	Service Delivery Point (Community) VCT Mod: 10-14, Male, Negative	109
	Service Delivery Point (Community) VCT Mod: 10-14, Male, Positive	9
	Service Delivery Point (Community) VCT Mod: 15-19, Female, Negative	1,051
	Service Delivery Point (Community) VCT Mod: 15-19, Female, Positive	40
	Service Delivery Point (Community) VCT Mod: 15-19, Male, Negative	946
	Service Delivery Point (Community) VCT Mod: 15-19, Male, Positive	13
	Service Delivery Point (Community) VCT Mod: 20-24, Female, Negative	1,576
	Service Delivery Point (Community) VCT Mod: 20-24, Female, Positive	162
	Service Delivery Point (Community) VCT Mod: 20-24, Male, Negative	1,681
	Service Delivery Point (Community) VCT Mod: 20-24, Male, Positive	80
	Service Delivery Point (Community) VCT Mod: 50+, Female, Negative	105
	Service Delivery Point (Community) VCT Mod: 50+, Female, Positive	13
	Service Delivery Point (Community) VCT Mod: 50+, Male, Negative	105



	Service Delivery Point (Community) VCT Mod: 50+, Male, Positive	13
	Service Delivery Point (Community) VCT Mod: <1, Negative	72
	Service Delivery Point (Community) VCT Mod: <1, Positive	11
	Service Delivery Point (Community) VCT Mod: 1-9, Negative	254
	Service Delivery Point (Community) VCT Mod: 1-9, Positive	18
	HTS_TST_N_DSD_EW_Age_Sex_ Result <1, Unknown Sex, Negative	701
	HTS_TST_N_DSD_EW_Age_Sex_ Result <1, Unknown Sex, Positive	6
	HTS_TST_N_DSD_EW_Age_Sex_ Result 10-14, Female, Negative	2,723
	HTS_TST_N_DSD_EW_Age_Sex_ Result 10-14, Female, Positive	25
	HTS_TST_N_DSD_EW_Age_Sex_ Result 10-14, Male, Negative	2,803
	HTS_TST_N_DSD_EW_Age_Sex_ Result 10-14, Male, Positive	28
	HTS_TST_N_DSD_EW_Age_Sex_ Result 15-19, Female, Negative	771
	HTS_TST_N_DSD_EW_Age_Sex_ Result 15-19, Female, Positive	22
	HTS_TST_N_DSD_EW_Age_Sex_ Result 15-19, Male, Negative	348
	HTS_TST_N_DSD_EW_Age_Sex_ Result 15-19, Male, Positive	7
	HTS_TST_N_DSD_EW_Age_Sex_ Result 1-9, Unknown Sex, Negative	2,154
	HTS_TST_N_DSD_EW_Age_Sex_ Result 1-9, Unknown Sex, Positive	21



HTS_TST_N_DSD_EW_Age_Sex_ Result 20-24, Female, Negative	1,474
HTS_TST_N_DSD_EW_Age_Sex_ Result 20-24, Female, Positive	38
HTS_TST_N_DSD_EW_Age_Sex_ Result 20-24, Male, Negative	695
HTS_TST_N_DSD_EW_Age_Sex_ Result 20-24, Male, Positive	18
HTS_TST_N_DSD_EW_Age_Sex_ Result 25-29, Female, Negative	1,880
HTS_TST_N_DSD_EW_Age_Sex_ Result 25-29, Female, Positive	61
HTS_TST_N_DSD_EW_Age_Sex_ Result 25-29, Male, Negative	1,102
HTS_TST_N_DSD_EW_Age_Sex_ Result 25-29, Male, Positive	24
HTS_TST_N_DSD_EW_Age_Sex_ Result 30-34, Female, Negative	2,087
HTS_TST_N_DSD_EW_Age_Sex_ Result 30-34, Female, Positive	54
HTS_TST_N_DSD_EW_Age_Sex_ Result 30-34, Male, Negative	1,215
HTS_TST_N_DSD_EW_Age_Sex_ Result 30-34, Male, Positive	75
HTS_TST_N_DSD_EW_Age_Sex_ Result 35-39, Female, Negative	1,655
HTS_TST_N_DSD_EW_Age_Sex_ Result 35-39, Female, Positive	38
HTS_TST_N_DSD_EW_Age_Sex_ Result 35-39, Male, Negative	1,201
HTS_TST_N_DSD_EW_Age_Sex_ Result 35-39, Male, Positive	41
HTS_TST_N_DSD_EW_Age_Sex_ Result 40-49, Female, Negative	1,010



HTS_TST_N_DSD_EW_Age_Sex_	49
Result 40-49, Female, Positive	
HTS_TST_N_DSD_EW_Age_Sex_	1,177
Result 40-49, Male, Negative	
HTS_TST_N_DSD_EW_Age_Sex_	38
Result 40-49, Male, Positive	
HTS_TST_N_DSD_EW_Age_Sex_	469
Result 50+, Female, Negative	
HTS_TST_N_DSD_EW_Age_Sex_	10
Result 50+, Female, Positive	
HTS_TST_N_DSD_EW_Age_Sex_	1,033
Result 50+, Male, Negative	
HTS_TST_N_DSD_EW_Age_Sex_	31
Result 50+, Male, Positive	
HTS_TST_N_DSD_Index_Age_Sex_	4,521
Result 25-29, Female, Negative	
HTS_TST_N_DSD_Index_Age_Sex_	1,001
Result 25-29, Female, Positive	
HTS_TST_N_DSD_Index_Age_Sex_	2,533
Result 25-29, Male, Negative	
HTS_TST_N_DSD_Index_Age_Sex_	521
Result 25-29, Male, Positive	
HTS_TST_N_DSD_Index_Age_Sex_	5,378
Result 30-34, Female, Negative	
HTS_TST_N_DSD_Index_Age_Sex_	1,069
Result 30-34, Female, Positive	
HTS_TST_N_DSD_Index_Age_Sex_	3,149
Result 30-34, Male, Negative	
HTS_TST_N_DSD_Index_Age_Sex_	765
Result 30-34, Male, Positive	
HTS_TST_N_DSD_Index_Age_Sex_	4,120
Result 35-39, Female, Negative	
HTS_TST_N_DSD_Index_Age_Sex_	818
Result 35-39, Female, Positive	



HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	2,983
HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	646
HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	2,472
HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	567
HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	2,678
HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	541
HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	4,364
HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	230
HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	2,458
HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	132
HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	4,829
HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	250
HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	2,916
HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	180
HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	3,778
HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	188
HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	2,763



HTS_TST_N_DSD_Inpat_Age_Sex _Result 35-39, Male, Positive	147
HTS_TST_N_DSD_Inpat_Age_Sex _Result 40-49, Female, Negative	2,320
HTS_TST_N_DSD_Inpat_Age_Sex _Result 40-49, Female, Positive	139
HTS_TST_N_DSD_Inpat_Age_Sex _Result 40-49, Male, Negative	2,480
HTS_TST_N_DSD_Inpat_Age_Sex _Result 40-49, Male, Positive	129
HTS_TST_N_DSD_MbMod_Age_ Sex_Result 25-29, Female, Negative	1,395
HTS_TST_N_DSD_MbMod_Age_ Sex_Result 25-29, Female, Positive	107
HTS_TST_N_DSD_MbMod_Age_ Sex_Result 25-29, Male, Negative	1,249
HTS_TST_N_DSD_MbMod_Age_ Sex_Result 25-29, Male, Positive	50
HTS_TST_N_DSD_MbMod_Age_ Sex_Result 30-34, Female, Negative	1,464
HTS_TST_N_DSD_MbMod_Age_ Sex_Result 30-34, Female, Positive	73
HTS_TST_N_DSD_MbMod_Age_ Sex_Result 30-34, Male, Negative	770
HTS_TST_N_DSD_MbMod_Age_ Sex_Result 30-34, Male, Positive	176
HTS_TST_N_DSD_MbMod_Age_ Sex_Result 35-39, Female, Negative	1,390
HTS_TST_N_DSD_MbMod_Age_ Sex_Result 35-39, Female, Positive	56



	Sex_Result 35-39, Female, Positive	
	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Negative	900
	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Positive	85
	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Negative	761
	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Positive	102
	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Negative	1,305
	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Positive	69
	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative	219
	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Positive	51
	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	206
	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Positive	17
	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Negative	233
	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Positive	32
	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	116



HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Positive	87
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Negative	225
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Positive	28
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	151
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Positive	35
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Negative	128
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Positive	52
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Negative	233
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Positive	31
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	13,083
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	844
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	7,892
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	466
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	14,025



HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	944
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	8,745
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	571
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	10,650
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	713
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	7,855
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	521
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	6,516
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	437
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	6,806
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	492
HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Female, Negative	3,084
HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Female, Positive	94
HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Male, Negative	1,650



HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Male, Positive	52
HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Female, Negative	3,424
HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Female, Positive	106
HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Male, Negative	2,068
HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Male, Positive	64
HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Female, Negative	2,620
HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Female, Positive	78
HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Negative	1,882
HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Positive	58
HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Negative	1,570
HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Positive	48
HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Negative	1,584
HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Positive	48
HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	17,931



HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	451
HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	11,650
HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	279
HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	4,496
HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	119
HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	1,005
HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	43
HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	447
HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	98
HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	262
HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	37
HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	493
HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	91
HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	309



HTS_TST_N_DSD_TBC_Age_Sex _Result 30-34, Male, Positive	106
HTS_TST_N_DSD_TBC_Age_Sex _Result 35-39, Female, Negative	391
HTS_TST_N_DSD_TBC_Age_Sex _Result 35-39, Female, Positive	74
HTS_TST_N_DSD_TBC_Age_Sex _Result 35-39, Male, Negative	321
HTS_TST_N_DSD_TBC_Age_Sex _Result 35-39, Male, Positive	66
HTS_TST_N_DSD_TBC_Age_Sex _Result 40-49, Female, Negative	266
HTS_TST_N_DSD_TBC_Age_Sex _Result 40-49, Female, Positive	73
HTS_TST_N_DSD_TBC_Age_Sex _Result 40-49, Male, Negative	291
HTS_TST_N_DSD_TBC_Age_Sex _Result 40-49, Male, Positive	55
HTS_TST_N_DSD_VCT_Age_Sex _Result 25-29, Female, Negative	2,147
HTS_TST_N_DSD_VCT_Age_Sex _Result 25-29, Female, Positive	124
HTS_TST_N_DSD_VCT_Age_Sex _Result 25-29, Male, Negative	1,175
HTS_TST_N_DSD_VCT_Age_Sex _Result 25-29, Male, Positive	69
HTS_TST_N_DSD_VCT_Age_Sex _Result 30-34, Female, Negative	2,385
HTS_TST_N_DSD_VCT_Age_Sex _Result 30-34, Female, Positive	130
HTS_TST_N_DSD_VCT_Age_Sex _Result 30-34, Male, Negative	1,508
HTS_TST_N_DSD_VCT_Age_Sex _Result 30-34, Male, Positive	93



HTS_TST_N_DSD_VCT_Age_Sex _Result 35-39, Female, Negative	1,860
HTS_TST_N_DSD_VCT_Age_Sex _Result 35-39, Female, Positive	112
HTS_TST_N_DSD_VCT_Age_Sex _Result 35-39, Male, Negative	1,329
HTS_TST_N_DSD_VCT_Age_Sex _Result 35-39, Male, Positive	80
HTS_TST_N_DSD_VCT_Age_Sex _Result 40-49, Female, Negative	1,107
HTS_TST_N_DSD_VCT_Age_Sex _Result 40-49, Female, Positive	68
HTS_TST_N_DSD_VCT_Age_Sex _Result 40-49, Male, Negative	1,261
HTS_TST_N_DSD_VCT_Age_Sex _Result 40-49, Male, Positive	77
HTS_TST_N_DSD_VCTMod_Age_ Sex_Result 25-29, Female, Negative	1,051
HTS_TST_N_DSD_VCTMod_Age_ Sex_Result 25-29, Female, Positive	200
HTS_TST_N_DSD_VCTMod_Age_ Sex_Result 25-29, Male, Negative	1,051
HTS_TST_N_DSD_VCTMod_Age_ Sex_Result 25-29, Male, Positive	200
HTS_TST_N_DSD_VCTMod_Age_ Sex_Result 30-34, Female, Negative	631
HTS_TST_N_DSD_VCTMod_Age_ Sex_Result 30-34, Female, Positive	200
HTS_TST_N_DSD_VCTMod_Age_ Sex_Result 30-34, Male, Negative	631



	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Male, Positive	200
	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Female, Negative	525
	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Female, Positive	80
	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Male, Negative	525
	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Male, Positive	81
	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Female, Negative	315
	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Female, Positive	27
	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Male, Negative	315
	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Male, Positive	27
GEND_GBV_DSD	Number of people receiving post-GBV care	172
	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	56
	By type of service: Sexual Violence (Post-Rape Care)	116
	By PEP service provision (related to sexual violence services provided)	116
	<10, Female, Physical and/or Emotional Violence	17



	<10, Female, Sexual Violence (Post-Rape Care)	20
	<10, Male, Physical and/or Emotional Violence	5
	<10, Male, Sexual Violence (Post-Rape Care)	9
	10-14, Female, Physical and/or Emotional Violence	9
	10-14, Female, Sexual Violence (Post-Rape Care)	32
	10-14, Male, Physical and/or Emotional Violence	3
	10-14, Male, Sexual Violence (Post-Rape Care)	7
	15-19, Female, Physical and/or Emotional Violence	9
	15-19, Female, Sexual Violence (Post-Rape Care)	20
	15-19, Male, Physical and/or Emotional Violence	2
	15-19, Male, Sexual Violence (Post-Rape Care)	2
	20-24, Female, Physical and/or Emotional Violence	3
	20-24, Female, Sexual Violence (Post-Rape Care)	9
	20-24, Male, Physical and/or Emotional Violence	2
	20-24, Male, Sexual Violence (Post-Rape Care)	3
	GEND_GBV_N_DSD_Age_Sex_Vi olenceType_v3 25-29, Female, Physical and/or Emotional Violence	2
	GEND_GBV_N_DSD_Age_Sex_Vi	5



	olenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Physical and/or Emotional Violence	2
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Sexual Violence (Post-Rape Care)	2
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	2
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	3
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Sexual Violence (Post-Rape Care)	2
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	2
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	18,839
	Age/Sex: 10-14 Male	2,254
	Age/Sex: 15-17 Male	1,164
	By: Age/sex: Male 18-24	259
	By: Age/sex: Male 25+	454
	Age/Sex: 10-14 Female	2,364
	Age/Sex: 15-17 Female	1,448
	By: Age/sex: 18-24 Female	586
	By: Age/sex: 25+ Female	1,181
	Sum of Age/Sex disaggregates	7,230
	Age/Sex: <1	890



	Age/Sex: 1-9	8,236
	Program Completion: Active	18,466
	Program Completion: Graduation	373
OVC_HIVSTAT_DSD	OVC_HIVSTAT_DSD Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	71 %
	Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	13,447
	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	18,839
TB_ART_DSD	TB_ART_DSD Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	n/a
	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	2,411
	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1,148
	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB	1,263



	cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
TB_ART_TA	TB_ART_TA Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	n/a
	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	2,211
	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	998
	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1,213
TB_PREV_DSD	TB_PREV_DSD TB_PREV_DSD	100 %
	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	10,771
	The number of ART patients who were newly started on TB	10,771



	preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	
	By Age/Sex (Denominator): <15, Female	313
	By Age/Sex (Denominator): <15, Male	416
	By Age/Sex (Denominator): 15+, Female	4,615
	By Age/Sex (Denominator): 15+, Male	5,428
	By Age/Sex (Numerator): <15, Female	313
	By Age/Sex (Numerator): <15, Male	416
	By Age/Sex (Numerator): 15+, Female	4,615
	By Age/Sex (Numerator): 15+, Male	5,427
	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	9,148
	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	1,623
	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	9,148
	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART,	1,623



	New, Positive	
TX_TB_DSD	TX_TB_DSD The proportion of ART patients who were screened who are receiving TB treatment	0 %
	Number of ART patients who were screened for TB at least once during the reporting period	83,601
	Denominator: By Aggregated Age/Sex: <15, Female	831
	Denominator: By Aggregated Age/Sex: <15, Male	660
	Denominator: By Aggregated Age/Sex: 15+, Female	58,537
	Denominator: By Aggregated Age/Sex: 15+, Male	23,573
	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	1,939
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	1,802
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	137
	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	54,084
	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	5,128
	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New,	15,534



	TB Screen - Negative, Positive	
	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	8,855
TX_TB_TA	TX_TB_TA The proportion of ART patients who were screened who are receiving TB treatment	0 %
	Number of ART patients who were screened for TB at least once during the reporting period	119,113
	Denominator: By Aggregated Age/Sex: <15, Female	1,768
	Denominator: By Aggregated Age/Sex: <15, Male	2,017
	Denominator: By Aggregated Age/Sex: 15+, Female	81,286
	Denominator: By Aggregated Age/Sex: 15+, Male	34,039
	Denominator: By Specimen Sent: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	14,736
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	14,222
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	514
	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	83,302
	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive,	5,978



	Positive	
	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	23,850
	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	5,980
PMTCT_EID_DSD	PMTCT_EID_DSD Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (DSD)	n/a
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	3,679
	By infants who received a virologic test within 2 months of birth	2,943
	By infants who received their first virologic HIV test between 2 and 12 months of age	736
	Sum of Infant Age disaggregates	3,679
PMTCT_EID_TA	PMTCT_EID_TA Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (TA)	n/a
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	4,824
	By infants who received a virologic test within 2 months of birth	3,859
	By infants who received their first virologic HIV test between 2 and 12 months of age	965
	Sum of Infant Age disaggregates	4,824
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy	107,239



	(ART)	
	Age/Sex: 15-19 Male	530
	Age/Sex: 15-19 Female	1,249
	Age/Sex: <1	234
	Age/Sex: <1-9	1,982
	Age/Sex: 10-14 Male	2,298
	Age/Sex: 10-14 Female	2,575
	Age/Sex: 20-24 Male	966
	Age/Sex: 50+ Male	7,472
	Age/Sex: 20-24 Female	4,530
	Age/Sex: 50+ Female	12,158
	TX_CURR_N_DSD_Age_Sex_HIV Status 25-29, Female, Positive	8,495
	TX_CURR_N_DSD_Age_Sex_HIV Status 25-29, Male, Positive	2,047
	TX_CURR_N_DSD_Age_Sex_HIV Status 30-34, Female, Positive	12,166
	TX_CURR_N_DSD_Age_Sex_HIV Status 30-34, Male, Positive	3,472
	TX_CURR_N_DSD_Age_Sex_HIV Status 35-39, Female, Positive	12,882
	TX_CURR_N_DSD_Age_Sex_HIV Status 35-39, Male, Positive	4,636
	TX_CURR_N_DSD_Age_Sex_HIV Status 40-49, Female, Positive	19,223
	TX_CURR_N_DSD_Age_Sex_HIV Status 40-49, Male, Positive	10,324
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	146,775
	Age/Sex: 15-19 Male	665
	Age/Sex: 15-19 Female	1,753
	Sum of Age/Sex disaggregations	2,418



	Age/Sex: <1	247
	Age/Sex: 1-9	2,115
	Age/Sex: 10-14 Male	2,575
	Age/Sex: 10-14 Female	2,901
	Age/Sex: 20-24 Male	1,318
	Age/Sex: 50+ Male	10,073
	Age/Sex: 20-24 Female	6,461
	Age/Sex: 50+ Female	16,649
	TX_CURR_N_TA_Age_Sex_HIVSt atus 25-29, Female, Positive	11,962
	TX_CURR_N_TA_Age_Sex_HIVSt atus 25-29, Male, Positive	2,719
	TX_CURR_N_TA_Age_Sex_HIVSt atus 30-34, Female, Positive	17,134
	TX_CURR_N_TA_Age_Sex_HIVSt atus 30-34, Male, Positive	4,755
	TX_CURR_N_TA_Age_Sex_HIVSt atus 35-39, Female, Positive	18,092
	TX_CURR_N_TA_Age_Sex_HIVSt atus 35-39, Male, Positive	6,387
	TX_CURR_N_TA_Age_Sex_HIVSt atus 40-49, Female, Positive	26,837
	TX_CURR_N_TA_Age_Sex_HIVSt atus 40-49, Male, Positive	14,132
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	24,623
	By Age/Sex: <1	124
	By Age/Sex: 1-9	388
	By Age/Sex: 10-14 Male	517
	By Age/Sex: 15-19 Male	429
	By Age/Sex: 20-24 Male	865
	By Age/Sex: 50+ Male	1,372



	By Age/Sex: 10-14 Female	541
	By Age/Sex: 15-19 Female	1,115
	By Age/Sex: 20-24 Female	2,056
	By Age/Sex: 50+ Female	783
	Pregnancy status	4,351
	Breastfeeding status	32
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 25-29, Female, Positive	2,863
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 25-29, Male, Positive	1,461
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 30-34, Female, Positive	3,107
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 30-34, Male, Positive	1,832
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 35-39, Female, Positive	2,356
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 35-39, Male, Positive	1,718
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 40-49, Female, Positive	1,563
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 40-49, Male, Positive	1,533
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	40,797
	By Age/Sex: <1	54
	By Age/Sex: 1-9	164
	By Age/Sex: 10-14 Male	213
	By Age/Sex: 15-19 Male	852
	By Age/Sex: 20-24 Male	1,561
	By Age/Sex: 50+ Male	2,402
	By Age/Sex: 10-14 Female	216
	By Age/Sex: 15-19 Female	2,020



	By Age/Sex: 20-24 Female	3,602
	By Age/Sex: 50+ Female	1,213
	Sum of Age/Sex disaggregates	12,079
	Pregnancy status	9,706
	Breastfeeding status	563
	TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Female, Positive	5,032
	TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Male, Positive	2,622
	TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Female, Positive	5,512
	TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Male, Positive	3,247
	TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Female, Positive	4,110
	TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive	2,966
	TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Female, Positive	2,473
	TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Male, Positive	2,538
TX_PVLS_DSD	TX_PVLS_DSD Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	0 %
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	56,105
	Denominator: Indication: Routine	50,491



	Denominator: Indication: Targeted	5,614
	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	560
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	2,245
	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	560
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	2,244
	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	560
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	24,679
	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	560
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	24,678
TX_PVLS_TA	TX_PVLS_TA Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	0 %
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	64,790
	Denominator: Indication: Routine	58,322
	Denominator: Indication: Targeted	6,468
	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	642
	Denominator: Aggregate Age/Sex	640



	by Indication: <15 Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	641
	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	641
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	28,492
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	2,577
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	28,491
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	2,577
TX_RET_DSD	TX_RET_DSD Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	90 %
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	13,536
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	14,959
	Numerator by Status: Breastfeeding	722
	Denominator by Status: Breastfeeding	804
	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after	199



	initiating ART)	
	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	5,237
	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	298
	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	7,771
	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	217
	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	5,856
	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the	322



	beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	8,529
TX_RET_TA	TX_RET_TA Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	90 %
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	32,861
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	36,598
	Numerator by Status: Breastfeeding	1,957
	Denominator by Status: Breastfeeding	2,184
	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	540



	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	12,604
	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	811
	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	18,906
	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	611
	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	14,168
	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	921

Approved



	including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	20,898



Partners and Implementing Mechanisms

Partner List

Mech ID	Partner Name	Organization Type	Agency	Funding Source	Planned Funding
12937	U.S. Peace Corps	Other USG Agency	U.S. Peace Corps	GHP-State	6,623
14127	WHO/AFRO	Multi-lateral Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
16743	Care International	NGO	U.S. Agency for International Development	GHP-State, GHP-USAID	3,798,486
16744	Catholic Relief Services	FBO	U.S. Agency for International Development	GHP-State, GHP-USAID	1,809,597
17361	Cameroon Baptist Convention Health Board	FBO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	10,441,447
17365	Metabiota	Private Contractor	U.S. Department of Defense	GHP-State	1,314,969
18195	Chemonics International	Private Contractor	U.S. Agency for International Development	GHP-State	736,941



18228	Cameroon Baptist Convention Health Board	FBO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	2,116,987
18229	NACC	Implementing Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,199,851
18230	Global Health Systems Solutions	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,162,853
18667	TBD	TBD	Redacted	Redacted	Redacted
70028	TBD	TBD	Redacted	Redacted	Redacted
70029	World Health Organization	Multi-lateral Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	25,000
70030	UNICEF	Multi-lateral Agency	U.S. Department of Health and Human Services/Centers for Disease Control and	GHP-State	92,953



			Prevention		
70031	TBD	TBD	Redacted	Redacted	Redacted
70032	TBD	TBD	Redacted	Redacted	Redacted
70035	TBD	TBD	Redacted	Redacted	Redacted
70036	TBD	TBD	Redacted	Redacted	Redacted
70037	TBD	TBD	Redacted	Redacted	Redacted
80015	Remote Medical International	Private Contractor	U.S. Agency for International Development	GHP-State	128,000
80016	Chemonics International	Private Contractor	U.S. Agency for International Development	GHP-State	678,714
80023	University of California at San Francisco	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
80042	TBD	TBD	Redacted	Redacted	Redacted



Implementing Mechanism(s)

Implementing Mechanism Details

Mechanism ID: 12937	Mechanism Name: Capacity Strengthening for Peace Corps Volunteers and Counterparts
Funding Agency: PC	Procurement Type: USG Core
Prime Partner Name: U.S. Peace Corps	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 6,623	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 315,585	
Total All Funding Sources and Applied Pipeline Amount: 322,208	
Funding Source	Funding Amount
GHP-State	6,623

Cross-Cutting Budget Attribution(s)

Adolescent Girls and Young Women (AGYW)	6,623
---	-------

Budget Code Information

Mechanism ID:	12937	
Mechanism Name:	Capacity Strengthening for Peace Corps Volunteers and Counterparts	
Prime Partner Name:	U.S. Peace Corps	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0



Strategic Area	Budget Code	Planned Amount
Care	HKID	6,623
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount



Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	17,733
PP_PREV_TA	Age/sex: 10-14 Male	1,373
PP_PREV_TA	Age/sex: 15-19 Male	1,482
PP_PREV_TA	Age/sex: 20-24 Male	1,816
PP_PREV_TA	Age/sex: 50+ Male	710
PP_PREV_TA	Age/sex: 10-14 Female	2,246
PP_PREV_TA	Age/sex: 15-19 Female	2,748
PP_PREV_TA	Age/sex: 20-24 Female	1,983
PP_PREV_TA	Age/sex: 50+ Female	889
PP_PREV_TA	Sum of Age/Sex disaggregates	13,247



PP_PREV_TA	PP_PREV_N_TA_Age_Sex_v2 25-29, Female	618
PP_PREV_TA	PP_PREV_N_TA_Age_Sex_v2 25-29, Male	504
PP_PREV_TA	PP_PREV_N_TA_Age_Sex_v2 30-34, Female	617
PP_PREV_TA	PP_PREV_N_TA_Age_Sex_v2 30-34, Male	504
PP_PREV_TA	PP_PREV_N_TA_Age_Sex_v2 35-39, Female	617
PP_PREV_TA	PP_PREV_N_TA_Age_Sex_v2 35-39, Male	504
PP_PREV_TA	PP_PREV_N_TA_Age_Sex_v2 40-49, Female	617
PP_PREV_TA	PP_PREV_N_TA_Age_Sex_v2 40-49, Male	504
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	3,111
OVC_SERV_DSD	Age/Sex: 10-14 Male	414
OVC_SERV_DSD	Age/Sex: 15-17 Male	368
OVC_SERV_DSD	By: Age/sex: Male 18-24	145
OVC_SERV_DSD	By: Age/sex: Male 25+	117
OVC_SERV_DSD	Age/Sex: 10-14 Female	413
OVC_SERV_DSD	Age/Sex: 15-17 Female	388
OVC_SERV_DSD	By: Age/sex: 18-24 Female	336
OVC_SERV_DSD	By: Age/sex: 25+ Female	308
OVC_SERV_DSD	Sum of Age/Sex disaggregates	1,583
OVC_SERV_DSD	Age/Sex: <1	9
OVC_SERV_DSD	Age/Sex: 1-9	610
OVC_SERV_DSD	Program Completion: Active	3,053
OVC_SERV_DSD	Program Completion: Graduation	58

Implementing Mechanism Details

Mechanism ID: 14127	Mechanism Name: WHO Cameroon
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: WHO/AFRO	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:



Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 14127 Mechanism Name: WHO Cameroon Prime Partner Name: WHO/AFRO		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0



Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount



Treatment	PDTX	0
-----------	------	---

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16743	Mechanism Name: Continuum of Prevention, Care, and Treatment for HIV/AIDS with MARPs in Cameroon (CHAMP)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Care International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 3,798,486	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 3,798,486	
Funding Source	Funding Amount
GHP-State	3,133,121
GHP-USAID	665,365

Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	698,984
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Monitoring and evaluation of MSM/TG programs
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for



	MSM/TG
Key Populations: FSW	2,218,378
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Monitoring and evaluation of SW programs
Gender: GBV	197,085
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Food and Nutrition: Policy, Tools, and Service Delivery	15,154
Adolescent Girls and Young Women (AGYW)	112,827
Condom programming	63,177
Human Resources for Health	646,642
Water	14,746

Budget Code Information

Mechanism ID: Mechanism Name: Prime Partner Name:	16743 Continuum of Prevention, Care, and Treatment for HIV/AIDS with MARPs in Cameroon (CHAMP) Care International	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	1,413,994



Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	25,746
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	249,701
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	1,108,964
Strategic Area	Budget Code	Planned Amount



Prevention	HVOP	1,000,081
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	2,077
PrEP_NEW_DSD	Male 15-19	92
PrEP_NEW_DSD	Male 20-24	145
PrEP_NEW_DSD	Male 50+	42
PrEP_NEW_DSD	Female 15-19	116
PrEP_NEW_DSD	Female 20-24	166
PrEP_NEW_DSD	Female 50+	62
PrEP_NEW_DSD	FSW	1,158
PrEP_NEW_DSD	MSM	919
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	241



PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	175
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	241
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	175
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	166
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	145
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	166
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Male	145
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	29,320
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	9,773
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	19,547
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	21,436
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	566
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	33
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	424
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	28
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	849



HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	67
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	707
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	56
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	71
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	11
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	70
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	11
HTC_TST_DSD	By Key Population: FSW, Negative	7,553
HTC_TST_DSD	By Key Population: FSW, Positive	1,033
HTC_TST_DSD	By Key Population: MSM, Negative	4,098
HTC_TST_DSD	By Key Population: MSM, Positive	511
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	78
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	17
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	59
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	12
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	118
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	25
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	97
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	22



HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	10
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	9
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 10-14, Female, Negative	290
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 10-14, Female, Positive	7
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 10-14, Male, Negative	109
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 10-14, Male, Positive	9
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Female, Negative	1,051
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Female, Positive	40
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Male, Negative	946
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Male, Positive	13
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Female, Negative	1,576
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Female, Positive	162
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Male, Negative	1,681
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Male, Positive	80
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Female, Negative	105



HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Female, Positive	13
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Male, Negative	105
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Male, Positive	13
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: <1, Negative	72
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: <1, Positive	11
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 1-9, Negative	254
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 1-9, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Negative	849
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Positive	61
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Negative	566
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Positive	50
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Negative	849
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Positive	62
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Negative	565
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Positive	50
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Negative	707
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Positive	45



HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Negative	354
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Positive	39
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Negative	283
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Positive	22
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Negative	212
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Positive	23
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative	117
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Positive	26
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	79
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Positive	17
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Negative	118
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Positive	26
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	78
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Negative	98
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Positive	22
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	49



HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Negative	39
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Negative	29
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Female, Negative	1,051
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Female, Positive	200
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Male, Negative	1,051
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Male, Positive	200
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Female, Negative	631
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Female, Positive	200
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Male, Negative	631
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Male, Positive	200
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Female, Negative	525
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Female, Positive	80
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Male, Negative	525
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Male, Positive	81



HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Female, Negative	315
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Female, Positive	27
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Male, Negative	315
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Male, Positive	27
HTS_SELF_DSD	HTS_SELF_N_DSD	2,012
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	41
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	61
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	101
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	101
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	202
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	201
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	181
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	181
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	181
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	42
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	158
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	40
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	160



	Male, Unassisted	
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	39
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	161
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted	39
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	123
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	866
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	1,146

Implementing Mechanism Details

Mechanism ID: 16744	Mechanism Name: Key Interventions for Developing Systems and Services for Orphans and Vulnerable Children populations in Cameroon (KIDSS)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Catholic Relief Services	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 1,809,597	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,809,597	
Funding Source	Funding Amount
GHP-State	1,275,084
GHP-USAID	534,513

Cross-Cutting Budget Attribution(s)

Gender: GBV	61,099
-------------	--------



Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Economic Strengthening	12,556
Adolescent Girls and Young Women (AGYW)	159,670
Food and Nutrition: Policy, Tools, and Service Delivery	141,265
Education	86,015
Water	23,627
Food and Nutrition: Commodities	23,627
Human Resources for Health	788,325

Budget Code Information

Mechanism ID: 16744 Mechanism Name: Key Interventions for Developing Systems and Services for Orphans and Vulnerable Children populations in Cameroon Prime Partner Name: (KIDSS) Catholic Relief Services		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	1,414,966
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	394,631
Strategic Area	Budget Code	Planned Amount



Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0



Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	15,728
OVC_SERV_DSD	Age/Sex: 10-14 Male	1,840
OVC_SERV_DSD	Age/Sex: 15-17 Male	796
OVC_SERV_DSD	By: Age/sex: Male 18-24	114
OVC_SERV_DSD	By: Age/sex: Male 25+	337
OVC_SERV_DSD	Age/Sex: 10-14 Female	1,951
OVC_SERV_DSD	Age/Sex: 15-17 Female	1,060
OVC_SERV_DSD	By: Age/sex: 18-24 Female	250
OVC_SERV_DSD	By: Age/sex: 25+ Female	873
OVC_SERV_DSD	Sum of Age/Sex disaggregates	5,647
OVC_SERV_DSD	Age/Sex: <1	881
OVC_SERV_DSD	Age/Sex: 1-9	7,626
OVC_SERV_DSD	Program Completion: Active	15,413
OVC_SERV_DSD	Program Completion: Graduation	315
OVC_HIVSTAT_DSD	Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	13,447
OVC_HIVSTAT_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	15,728



Implementing Mechanism Details

Mechanism ID: 17361	Mechanism Name: CBCHB - PMTCT-ART Center-Littoral 2015
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Cameroon Baptist Convention Health Board	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 10,441,447	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 10,441,447	
Funding Source	Funding Amount
GHP-State	10,441,447

Cross-Cutting Budget Attribution(s)

Water	40,903
Human Resources for Health	504,453

Budget Code Information

Mechanism ID: 17361		
Mechanism Name: CBCHB - PMTCT-ART Center-Littoral 2015		
Prime Partner Name: Cameroon Baptist Convention Health Board		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	1,006,029
Strategic Area	Budget Code	Planned Amount



Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	301,808
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	1,006,023
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0



Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	381,174
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	7,042,193
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	704,220

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	1,225
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	24,819
PMTCT_ART_DSD	New on ART	571
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	654
PMTCT_ART_TA	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	1,785
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	36,026



PMTCT_ART_TA	New on ART	969
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	816
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	24,819
PMTCT_STAT_DSD	Number of new ANC and L&D clients	25,980
PMTCT_STAT_DSD	By Age (Denominator): 10-14	278
PMTCT_STAT_DSD	By Age (Denominator): <15-19	2,858
PMTCT_STAT_DSD	By Age (Denominator): 20-24	6,740
PMTCT_STAT_DSD	By Number of known positives: 15-19	39
PMTCT_STAT_DSD	By Number of known positives: 20-24	113
PMTCT_STAT_DSD	By Number of new positives: 15-19	56
PMTCT_STAT_DSD	By Number of new positives: 20-24	111
PMTCT_STAT_DSD	By Number of new negative: <10	251
PMTCT_STAT_DSD	By Number of new negative: 10-14	251
PMTCT_STAT_DSD	By Number of new negative: 15-19	2,586
PMTCT_STAT_DSD	By Number of new negative: 20-24	6,366
PMTCT_STAT_DSD	By Age (Numerator): <10	251
PMTCT_STAT_DSD	By Age (Numerator): 10-14	251
PMTCT_STAT_DSD	By Age (Numerator): 15-19	2,670
PMTCT_STAT_DSD	By Age (Numerator): 20-24	6,567
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	9,073
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	4,417
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	2,086
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	528
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	254
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	7,983
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	224
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	218



PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	4,011
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	133
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	142
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	1,656
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	79
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	45
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	477
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	18
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	8,460
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	4,336
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	1,855
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	524
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	36,026
PMTCT_STAT_TA	Number of new ANC and L&D clients	38,433
PMTCT_STAT_TA	By Age (Denominator): 10-14	423
PMTCT_STAT_TA	By Age (Denominator): 15-19	4,238
PMTCT_STAT_TA	By Age (Denominator): 20-24	9,954
PMTCT_STAT_TA	By known positives: 15-19	23
PMTCT_STAT_TA	By known positives: 20-24	140
PMTCT_STAT_TA	By new positives: 15-19	129
PMTCT_STAT_TA	By new positives: 20-24	218
PMTCT_STAT_TA	By new negatives: <10	379
PMTCT_STAT_TA	By new negatives: 10-14	379



PMTCT_STAT_TA	By new negatives: 15-19	3,790
PMTCT_STAT_TA	By new negatives: 20-24	9,261
PMTCT_STAT_TA	By Age (Numerator): <10	379
PMTCT_STAT_TA	By Age (Numerator): 10-14	379
PMTCT_STAT_TA	By Age (Numerator): : 15-19	3,916
PMTCT_STAT_TA	By Age (Numerator): 20-24	9,563
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 25-29, Female	13,379
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 30-34, Female	6,517
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 35-39, Female	3,095
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 40-49, Female	827
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	300
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	11,613
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	431
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	258
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	5,840
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	258
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	182
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	2,421
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	154
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	40
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	727
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult	43



	40-49, Female, Newly Identified Positive	
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 25-29, Female	12,309
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 30-34, Female	6,295
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 35-39, Female	2,696
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 40-49, Female	794
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	321,545
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	3,783
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	17
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	4,043
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	17
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	1,133
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	57
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	472
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	40
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	1,912
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	101
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	837
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	65
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	716



HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	44
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	1,263
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	62
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	992
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	3,052
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	19,580
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	82
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	20,212
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	94
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	3,426
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	220
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	1,548
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	89
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	5,618
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	353
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	2,389
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	183



HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	1,800
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	110
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	3,751
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	217
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Negative	5,278
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	30
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	15,649
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	66
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Female, Negative	642
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Female, Positive	19
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Male, Negative	260
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Male, Positive	9
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Female, Negative	1,133
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Female, Positive	36
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Male, Negative	491
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Male, Positive	16
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Female, Negative	369



HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Female, Positive	12
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Male, Negative	722
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Male, Positive	22
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	5,340
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	34
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	117
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Positive	26
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	138
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	29
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	189
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	42
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	42
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	200
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	49
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	106
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	21
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	75



HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	140
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	28
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Negative	43
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	132
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	22
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	4,764
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	82
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	5,090
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	89
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	1,211
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	257
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	483
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	107
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	2,071
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	425
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	916
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	194
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female,	709



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	150
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	1,383
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	291
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	1,238
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Positive	24
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	3,839
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	65
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	105
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	4,860
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	112
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	21,745
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	243
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	6,755
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	54
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	7,209
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	54
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	556
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	31
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	321
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	22



HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	967
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	50
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	428
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	30
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	352
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	18
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	855
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	39
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Negative	1,788
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Positive	14
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	5,459
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	41
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result <1, Unknown Sex, Negative	393
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result <1, Unknown Sex, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 10-14, Female, Negative	1,543
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 10-14, Female, Positive	15
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 10-14, Male, Negative	1,544
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 10-14, Male, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Female, Negative	446



HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Female, Positive	14
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Male, Negative	181
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Male, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 1-9, Unknown Sex, Negative	1,204
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 1-9, Unknown Sex, Positive	14
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Female, Negative	793
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Female, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Male, Negative	343
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Female, Negative	1,080
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Female, Positive	31
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Male, Negative	573
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Male, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Female, Negative	1,196
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Female, Positive	33
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Male, Negative	721
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Male, Positive	15



HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Female, Negative	916
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Female, Positive	23
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Male, Negative	656
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Male, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Female, Negative	548
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Female, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Male, Negative	552
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Male, Positive	19
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Female, Negative	258
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Female, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Male, Negative	507
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Male, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	2,793
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	602
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	1,519
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	325
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	3,236



HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	664
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	1,940
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	410
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	2,473
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	507
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	1,807
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	377
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	1,449
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	311
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	1,512
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	313
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	2,614
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	135
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	1,405
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	80
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	2,891
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	153



HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	1,773
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	92
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	2,236
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	114
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	1,627
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	85
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	1,362
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	78
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	1,368
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	76
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	7,537
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	487
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	4,095
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	279
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	8,328
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	548
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	5,028



HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	328
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	6,370
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	421
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	4,578
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	296
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	3,817
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	256
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	3,855
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	263
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Female, Negative	1,542
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Female, Positive	47
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Male, Negative	825
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Male, Positive	26
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Female, Negative	1,712
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Female, Positive	53
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Male, Negative	1,034
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Male, Positive	32



HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Female, Negative	1,310
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Female, Positive	39
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Negative	941
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Positive	29
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Negative	785
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Positive	24
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Negative	792
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Positive	24
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	10,480
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	241
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	6,822
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	154
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	2,217
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	65
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	475
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	28
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	256



HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	46
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	144
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	30
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	282
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	56
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	177
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	25
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	219
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	50
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	166
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	161
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	34
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	158
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	31
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	1,315
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	84



HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	703
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	41
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	1,461
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	89
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	883
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	43
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	1,119
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive	61
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	803
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	42
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	668
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Positive	44
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	728
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	43
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	145,945
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	405
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Male,	434



	Negative	
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	599
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	37
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	233
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	10
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	1,061
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	69
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	456
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	23
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	342
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	15
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	670
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	40
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: <1, Negative	109
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 1-9, Negative	323
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	4,328
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	14
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	4,620
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	14



	Male, Positive	
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	3,390
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	341
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	1,372
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	131
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	5,996
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	601
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	2,598
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	255
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	1,957
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	186
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	3,812
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	379
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: <1, Negative	1,133
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: <1, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 1-9, Negative	3,486
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 1-9, Positive	11
HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Negative	3,137



HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Positive	49
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Female, Negative	9
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Male, Negative	10
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Female, Negative	4
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Male, Negative	1
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female, Negative	32
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female, Positive	4
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Male, Negative	9
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Female, Negative	9
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Female, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Negative	15
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) TB: 1-9, Negative	3
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Female, Negative	228
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Female, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Male, Negative	237
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Male, Positive	3
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Negative	92
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Positive	19



	Positive	
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Male, Negative	42
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Male, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Negative	195
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Positive	40
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Negative	90
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Positive	13
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Female, Negative	59
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Female, Positive	5
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Male, Negative	139
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Male, Positive	25
HTC_TST_TA	Service Delivery Point (Facility) Index: <1, Negative	57
HTC_TST_TA	Service Delivery Point (Facility) Index: 1-9, Negative	177
HTC_TST_TA	Service Delivery Point (Facility) Index: 1-9, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) ANC: 10-14, Negative	24
HTC_TST_TA	Service Delivery Point (Facility) ANC: 15-19, Negative	3,930
HTC_TST_TA	Service Delivery Point (Facility) ANC: 15-19, Positive	109
HTC_TST_TA	Service Delivery Point (Facility) ANC: 20-24, Negative	3,930
HTC_TST_TA	Service Delivery Point (Facility) ANC: 20-24, Positive	236
HTC_TST_TA	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	2,265
HTC_TST_TA	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	10



HTC_TST_TA	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	2,418
HTC_TST_TA	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	12
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	294
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	107
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	526
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	18
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	229
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) VCT: 50+, Female, Negative	135
HTC_TST_TA	Service Delivery Point (Facility) VCT: 50+, Male, Negative	324
HTC_TST_TA	Service Delivery Point (Facility) VCT: 50+, Male, Positive	6
HTC_TST_TA	Service Delivery Point (Facility) VCT: <1, Negative	565
HTC_TST_TA	Service Delivery Point (Facility) VCT: <1, Positive	3
HTC_TST_TA	Service Delivery Point (Facility) VCT: 1-9, Negative	1,824
HTC_TST_TA	Service Delivery Point (Facility) VCT: 1-9, Positive	10
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 10-14, Female, Negative	48
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 10-14, Male, Negative	50
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 15-19, Female, Negative	27



HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 15-19, Male, Negative	6
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 1-9, Unknown Sex, Negative	40
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result <1, Unknown Sex, Negative	10
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 20-24, Female, Negative	49
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 20-24, Male, Negative	17
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 25-29, Female, Negative	66
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 25-29, Male, Negative	32
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 30-34, Female, Negative	78
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 30-34, Male, Negative	44
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 35-39, Female, Negative	55
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 35-39, Male, Negative	40
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 40-49, Female, Negative	32
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 40-49, Male, Negative	32
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 50+, Female, Negative	10
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 50+, Male, Negative	32
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Female, Negative	241
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Female, Positive	58



HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Male, Negative	146
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Male, Positive	23
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Female, Negative	268
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Female, Positive	54
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Male, Negative	147
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Male, Positive	57
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Female, Negative	213
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Female, Positive	45
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Male, Negative	157
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Male, Positive	35
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Female, Negative	128
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Female, Positive	40
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Male, Negative	164
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Male, Positive	33
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Female, Negative	1,438
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Female, Positive	107
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Male, Negative	772



HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Male, Positive	50
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Female, Negative	1,594
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Female, Positive	117
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Male, Negative	968
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Male, Positive	66
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Female, Negative	1,219
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Female, Positive	84
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Male, Negative	877
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Male, Positive	57
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Female, Negative	732
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Female, Positive	47
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Male, Negative	736
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Male, Positive	48
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Female, Negative	8,149
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Female, Positive	820
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Male, Negative	4,353
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Male, Positive	439



HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Female, Negative	9,060
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Female, Positive	901
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Male, Negative	5,469
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Male, Positive	552
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Female, Negative	6,924
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Female, Positive	689
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Male, Negative	4,984
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Male, Positive	501
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Female, Negative	4,154
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Female, Positive	411
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Male, Negative	4,192
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Male, Positive	415
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 25-29, Female, Negative	8,478
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 25-29, Female, Positive	236
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 30-34, Female, Negative	5,521
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 30-34, Female, Positive	167
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 35-39, Female, Negative	1,929



HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 35-39, Female, Positive	61
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 40-49, Female, Negative	372
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 40-49, Female, Positive	3
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Female, Negative	70
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Female, Positive	16
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Male, Negative	15
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Male, Positive	7
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Female, Negative	76
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Female, Positive	16
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Male, Negative	30
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Male, Positive	2
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Female, Negative	60
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Female, Positive	12
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Male, Negative	28
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Male, Positive	2
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Female, Negative	27
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Female, Positive	4



HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Male, Negative	16
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Male, Positive	6
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 25-29, Female, Negative	715
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 25-29, Female, Positive	28
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 25-29, Male, Negative	381
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 25-29, Male, Positive	7
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 30-34, Female, Negative	789
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 30-34, Female, Positive	34
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 30-34, Male, Negative	479
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 30-34, Male, Positive	14
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 35-39, Female, Negative	605
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 35-39, Female, Positive	20
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 35-39, Male, Negative	435
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 35-39, Male, Positive	11
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 40-49, Female, Negative	357
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 40-49, Female, Positive	8
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 40-49, Male, Negative	361



HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 40-49, Male, Positive	7
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	2,715
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	2,717
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	103
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,404
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	93
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,153
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	111
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,415
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	93
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,142
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,514
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	1,520
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Denominator: Total	47



	number of registered new and relapsed TB cases, during the reporting period)	
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	49
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	614
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	868
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	34
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	879
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	44
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	605
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,094
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	534
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	586
TB_ART_TA	The number of registered new and relapse TB cases	517



	with documented HIV-positive status who are on ART during TB treatment during the reporting period	
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	256
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	292
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	1,795
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	1,431
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	364
PMTCT_EID_DSD	Sum of Infant Age disaggregates	1,795
PMTCT_EID_TA	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	1,189
PMTCT_EID_TA	By infants who received a virologic test within 2 months of birth	934
PMTCT_EID_TA	By infants who received their first virologic HIV test between 2 and 12 months of age	255
PMTCT_EID_TA	Sum of Infant Age disaggregates	1,189
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	49,686
TX_CURR_DSD	Age/Sex: 15-19 Male	241
TX_CURR_DSD	Age/Sex: 15-19 Female	602
TX_CURR_DSD	Sum of age/sex disaggregates	843
TX_CURR_DSD	Age/Sex: <1	131
TX_CURR_DSD	Age/Sex: <1-9	941
TX_CURR_DSD	Age/Sex: 10-14 Male	1,148
TX_CURR_DSD	Age/Sex: 10-14 Female	1,291
TX_CURR_DSD	Age/Sex: 20-24 Male	462



TX_CURR_DSD	Age/Sex: 50+ Male	3,363
TX_CURR_DSD	Age/Sex: 20-24 Female	2,166
TX_CURR_DSD	Age/Sex: 50+ Female	5,554
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	3,990
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	923
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	5,711
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	1,595
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	6,029
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	2,138
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	8,931
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	4,712
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	32,989
TX_CURR_TA	Age/Sex: 15-19 Male	177
TX_CURR_TA	Age/Sex: 15-19 Female	440
TX_CURR_TA	Sum of Age/Sex disaggregations	617
TX_CURR_TA	Age/Sex: <1	23
TX_CURR_TA	Age/Sex: 1-9	166
TX_CURR_TA	Age/Sex: 10-14 Male	195
TX_CURR_TA	Age/Sex: 10-14 Female	221
TX_CURR_TA	Age/Sex: 20-24 Male	330
TX_CURR_TA	Age/Sex: 50+ Male	2,395
TX_CURR_TA	Age/Sex: 20-24 Female	1,545
TX_CURR_TA	Age/Sex: 50+ Female	3,924
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 25-29, Female,	2,832



	Positive	
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 25-29, Male, Positive	671
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 30-34, Female, Positive	4,041
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 30-34, Male, Positive	1,157
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 35-39, Female, Positive	4,261
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive	1,530
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 40-49, Female, Positive	6,299
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 40-49, Male, Positive	3,343
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	11,243
TX_NEW_DSD	By Age/Sex: <1	68
TX_NEW_DSD	By Age/Sex: 1-9	208
TX_NEW_DSD	By Age/Sex: 10-14 Male	270
TX_NEW_DSD	By Age/Sex: 15-19 Male	228
TX_NEW_DSD	By Age/Sex: 20-24 Male	427
TX_NEW_DSD	By Age/Sex: 50+ Male	615
TX_NEW_DSD	By Age/Sex: 10-14 Female	252
TX_NEW_DSD	By Age/Sex: 15-19 Female	552
TX_NEW_DSD	By Age/Sex: 20-24 Female	960
TX_NEW_DSD	By Age/Sex: 50+ Female	324
TX_NEW_DSD	Sum of Age/Sex disaggregates	3,628
TX_NEW_DSD	Pregnancy status	2,127
TX_NEW_DSD	Breastfeeding status	21
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	1,301
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	705



	Positive	
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	1,442
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	881
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	1,109
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	800
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	670
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	676
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	9,395
TX_NEW_TA	By Age/Sex: <1	19
TX_NEW_TA	By Age/Sex: 1-9	44
TX_NEW_TA	By Age/Sex: 10-14 Male	57
TX_NEW_TA	By Age/Sex: 15-19 Male	212
TX_NEW_TA	By Age/Sex: 20-24 Male	389
TX_NEW_TA	By Age/Sex: 50+ Male	566
TX_NEW_TA	By Age/Sex: 10-14 Female	55
TX_NEW_TA	By Age/Sex: 15-19 Female	500
TX_NEW_TA	By Age/Sex: 20-24 Female	877
TX_NEW_TA	By Age/Sex: 50+ Female	297
TX_NEW_TA	Sum of Age/Sex disaggregates	2,953
TX_NEW_TA	Pregnancy status	1,583
TX_NEW_TA	Breastfeeding status	116
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Female, Positive	1,175
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Male, Positive	649
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Female,	1,303



	Positive	
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Male, Positive	795
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Female, Positive	999
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive	727
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Female, Positive	614
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Male, Positive	615
HTS_SELF_DSD	HTS_SELF_N_DSD	12,545
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Female, Directly-Assisted	259
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Female, Unassisted	259
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Male, Directly-Assisted	259
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Male, Unassisted	259
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	259
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	390
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	259
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	390
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	1,261
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	1,141
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	1,141

HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	1,107
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	1,129
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	259
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	1,013
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	259
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	1,013
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	259
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	887
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted	135
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	765
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	5,399
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	7,146
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	5,123
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	5,123
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	165



TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	215
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	2,213
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	2,573
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	165
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	215
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	2,213
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	2,573
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	4,357
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	782
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	4,357
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	782
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	38,659
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	399
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	283
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	27,386
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	10,633
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	973
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	912
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	73
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	27,058
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	1,945
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV	7,748



	Life-long ART, New, TB Screen - Negative, Positive	
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	1,945
TX_TB_TA	Number of ART patients who were screened for TB at least once during the reporting period	27,346
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Female	222
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Male	206
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Female	18,472
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Male	8,528
TX_TB_TA	Denominator: By Specimen Sent: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	7,200
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	6,989
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	216
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	19,138
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	1,412
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	5,512
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	1,409

Implementing Mechanism Details

Mechanism ID: 17365	Mechanism Name: Strengthening Lab & MTCT Services in the military
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: Metabiota	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:



Total All Funding Sources: 1,314,969	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,314,969	
Funding Source	Funding Amount
GHP-State	1,314,969

Cross-Cutting Budget Attribution(s)

Gender: GBV	50,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Focus Area:	Post GBV Care
Water	25,000
Food and Nutrition: Policy, Tools, and Service Delivery	10,000
Condom programming	47,223
Adolescent Girls and Young Women (AGYW)	106,926
Human Resources for Health	146,462

Budget Code Information

Mechanism ID: 17365		
Mechanism Name: Strengthening Lab & MTCT Services in the military		
Prime Partner Name: Metabiota		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	409,641
Strategic Area	Budget Code	Planned Amount



Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	17,314
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	43,079
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	138,086
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	151,116



Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	27,207
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	86,571
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	424,641
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	17,314

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	154
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	2,308
PMTCT_ART_DSD	New on ART	39
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	115
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	2,308
PMTCT_STAT_DSD	Number of new ANC and L&D clients	2,429
PMTCT_STAT_DSD	By Age (Denominator): <15-19	291
PMTCT_STAT_DSD	By Age (Denominator): 20-24	632



PMTCT_STAT_DSD	By Number of known positives: 20-24	26
PMTCT_STAT_DSD	By Number of new positives: 20-24	4
PMTCT_STAT_DSD	By Number of new negative: 15-19	237
PMTCT_STAT_DSD	By Number of new negative: 20-24	581
PMTCT_STAT_DSD	By Age (Numerator): 15-19	237
PMTCT_STAT_DSD	By Age (Numerator): 20-24	611
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	777
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	486
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	219
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	24
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	31
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	689
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	21
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	37
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	431
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	12
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	5
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	194
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	12
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	5
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	22
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	741



PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	480
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	211
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	27
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	6,501
PP_PREV_DSD	Age/sex: 10-14 Male	13
PP_PREV_DSD	Age/sex: 15-19 Male	65
PP_PREV_DSD	Age/sex: 20-24 Male	774
PP_PREV_DSD	Age/sex: 50+ Male	564
PP_PREV_DSD	Age/sex: 10-14 Female	260
PP_PREV_DSD	Age/sex: 15-19 Female	650
PP_PREV_DSD	Age/sex: 20-24 Female	650
PP_PREV_DSD	Age/sex: 50+ Female	65
PP_PREV_DSD	Sum of Age/Sex disaggregates	3,041
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Female	330
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	1,245
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Female	130
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	650
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Female	130
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	520
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Female	130
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	325
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	30,226
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	4
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	3
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19,	50



	Female, Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	50
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	183
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	133
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	50
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	199
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	2
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	15
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	3
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	205
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	11
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	205
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	751
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	23
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	546



HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	11
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	205
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	820
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	34
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	77
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	70
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	323
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	160
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	1,030
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	54
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	1,045
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	485
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	38



HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	547
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	42
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Negative	32
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	377
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	23
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	453
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	9
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	12
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	9
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	9
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	32
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	24
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	9
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	35



HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	62
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	38
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	45
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	45
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	165
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	20
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	120
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	45
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	180
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	29
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	23
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	646
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	64
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	32
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	48
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	38



HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	6
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	38
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	140
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	13
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	102
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	6
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	38
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	153
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	19
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	7
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	247
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	576
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	14
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	14
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	52
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	38



HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	14
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	57
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Female, Negative	54
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Female, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Male, Negative	54
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Female, Negative	198
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Female, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Male, Negative	144
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Female, Negative	144
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Female, Positive	17
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Male, Negative	180
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Female, Negative	162
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Female, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Male, Negative	54



HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Male, Positive	46
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Female, Negative	180
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Female, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Male, Negative	144
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Male, Positive	17
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Female, Negative	126
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Female, Positive	29
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Male, Negative	288
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Male, Positive	17
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Female, Negative	54
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Male, Negative	216
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Male, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	120
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	39
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	150
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	135
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	10



HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	45
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	107
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	150
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	120
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	39
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	105
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	68
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	241
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	39
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	133
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	166
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	150
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	50
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	32



HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	166
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	133
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	116
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	20
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	266
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Negative	546
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Positive	46
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Negative	683
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Negative	615
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Negative	205
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Positive	126
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Negative	683
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Positive	11

HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Negative	546
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Positive	46
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Negative	478
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Positive	80
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Negative	1,093
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Positive	46
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative	102
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Positive	25
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	127
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Negative	115
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	38
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Positive	69
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Negative	127
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	102
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Positive	25



HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Negative	89
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Positive	44
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Negative	204
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Positive	25
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	901
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	58
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	1,200
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	33
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	583
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	65
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	607
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	50
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	347
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	36
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	445
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	38
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	330



HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	36
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	564
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	77
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	682
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	21
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	425
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	195
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	21
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	24
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	29
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	26
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	9
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	49



HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	29
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	24
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	21
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	31
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	47
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	38
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	47
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	42
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	14
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	47
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive	1

HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	38
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	33
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	76
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	2
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	591
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	657
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	11
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	337
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	9
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	234
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	12
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	376



TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	10
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	259
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	244
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	117
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	127
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	139
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	111
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	28
PMTCT_EID_DSD	Sum of Infant Age disaggregates	139
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	7,895
TX_CURR_DSD	Age/Sex: 15-19 Male	77
TX_CURR_DSD	Age/Sex: 15-19 Female	77
TX_CURR_DSD	Sum of age/sex disaggregates	154
TX_CURR_DSD	Age/Sex: <1	2
TX_CURR_DSD	Age/Sex: <1-9	121
TX_CURR_DSD	Age/Sex: 10-14 Male	28
TX_CURR_DSD	Age/Sex: 10-14 Female	23
TX_CURR_DSD	Age/Sex: 20-24 Male	77



TX_CURR_DSD	Age/Sex: 50+ Male	772
TX_CURR_DSD	Age/Sex: 20-24 Female	232
TX_CURR_DSD	Age/Sex: 50+ Female	1,081
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	541
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	232
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	772
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	309
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	849
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	386
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	1,389
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	927
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	2,167
TX_NEW_DSD	By Age/Sex: <1	4
TX_NEW_DSD	By Age/Sex: 1-9	4
TX_NEW_DSD	By Age/Sex: 10-14 Male	7
TX_NEW_DSD	By Age/Sex: 20-24 Male	42
TX_NEW_DSD	By Age/Sex: 50+ Male	167
TX_NEW_DSD	By Age/Sex: 10-14 Female	65
TX_NEW_DSD	By Age/Sex: 15-19 Female	42
TX_NEW_DSD	By Age/Sex: 20-24 Female	167
TX_NEW_DSD	By Age/Sex: 50+ Female	167
TX_NEW_DSD	Sum of Age/Sex disaggregates	657
TX_NEW_DSD	Pregnancy status	125
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29,	292



	Female, Positive	
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	83
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	250
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	104
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	167
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	146
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	250
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	210
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	6,528
TX_PVLS_DSD	Denominator: Indication: Routine	5,875
TX_PVLS_DSD	Denominator: Indication: Targeted	653
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	65
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	262
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	65
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	261
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	65
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	2,873
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	65



TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	2,872
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,944
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	2,162
TX_RET_DSD	Numerator by Status: Breastfeeding	31
TX_RET_DSD	Denominator by Status: Breastfeeding	35
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	17
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	783
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	25
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,088
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	19
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	935
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	28



	including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,145
HTS_SELF_DSD	HTS_SELF_N_DSD	1,000
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Female, Directly-Assisted	20
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Female, Unassisted	20
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Male, Directly-Assisted	20
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Male, Unassisted	20
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	20
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	30
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	20
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	30
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	50
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	50
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	50
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	90
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	90

HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	20
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	80
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	20
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	80
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	20
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	70
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted	10
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	60
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	430
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	570
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	539
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	539
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	8
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	10
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	213
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	309
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	8



TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	10
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	213
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	308
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	458
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	81
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	458
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	81
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	6,316
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	63
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	126
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	3,790
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	2,337
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	20
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	3
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	17
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	1,263
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	63
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	4,990

Implementing Mechanism Details

Mechanism ID: 18195	Mechanism Name: Global Health Supply Chain Program - GHSC-PSM
----------------------------	--



Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Chemonics International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 736,941	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 736,941	
Funding Source	Funding Amount
GHP-State	736,941

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 18195		
Mechanism Name: Global Health Supply Chain Program - GHSC-PSM		
Prime Partner Name: Chemonics International		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount



Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0



Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	50,176
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	686,765
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18228	Mechanism Name: ART services in 8 regions
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Cameroon Baptist Convention Health Board	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 2,116,987	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 2,116,987	
Funding Source	Funding Amount
GHP-State	2,116,987

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 18228		
Mechanism Name: ART services in 8 regions		
Prime Partner Name: Cameroon Baptist Convention Health Board		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	288,554
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	76,955
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount



Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	174,483
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	251,802
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	1,170,630
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	154,563

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_TA	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	2,572
PMTCT_ART_TA	Number of pregnant women with known HIV status	45,208



	(includes women who were tested for HIV and received their results)	
PMTCT_ART_TA	New on ART	1,177
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	1,395
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	45,208
PMTCT_STAT_TA	Number of new ANC and L&D clients	47,582
PMTCT_STAT_TA	By Age (Denominator): 10-14	67
PMTCT_STAT_TA	By Age (Denominator): 15-19	6,248
PMTCT_STAT_TA	By Age (Denominator): 20-24	13,654
PMTCT_STAT_TA	By known positives: 15-19	29
PMTCT_STAT_TA	By known positives: 20-24	157
PMTCT_STAT_TA	By new positives: 10-14	2
PMTCT_STAT_TA	By new positives: 15-19	68
PMTCT_STAT_TA	By new positives: 20-24	277
PMTCT_STAT_TA	By new negatives: 10-14	58
PMTCT_STAT_TA	By new negatives: 15-19	5,815
PMTCT_STAT_TA	By new negatives: 20-24	12,556
PMTCT_STAT_TA	By Age (Numerator): 10-14	64
PMTCT_STAT_TA	By Age (Numerator): : 15-19	5,936
PMTCT_STAT_TA	By Age (Numerator): 20-24	13,011
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 25-29, Female	13,859
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 30-34, Female	9,292
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 35-39, Female	3,731
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 40-49, Female	731
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	403
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	12,392
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	315
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult	489



	30-34, Female, Known at Entry Positive	
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	7,984
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	335
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	403
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	2,946
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	129
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	35
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	637
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	4
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 25-29, Female	13,171
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 30-34, Female	8,833
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 35-39, Female	3,497
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 40-49, Female	696
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	418,578
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	1,275
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	11
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	1,358
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	13
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	3,051



HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	212
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	1,232
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	80
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	5,389
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	390
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	2,337
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	158
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	1,762
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	119
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	3,432
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	241
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: <1, Negative	332
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: <1, Positive	3
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 1-9, Negative	1,019
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 1-9, Positive	9
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	5,001
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	34
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	5,339
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	36



HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	12,452
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	697
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	5,016
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	282
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	21,995
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	1,242
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	9,553
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	538
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	7,185
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	410
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	14,009
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	793
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: <1, Negative	1,309
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: <1, Positive	6
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 1-9, Negative	4,033
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 1-9, Positive	24
HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Negative	1,678
HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Positive	11



HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Female, Negative	38
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Female, Positive	8
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Male, Negative	43
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Male, Positive	10
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Female, Negative	37
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Female, Positive	13
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Male, Negative	23
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Male, Positive	3
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female, Negative	134
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female, Positive	39
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Male, Negative	47
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Male, Positive	6
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Female, Negative	42
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Female, Positive	14
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Negative	77
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Positive	6
HTC_TST_TA	Service Delivery Point (Facility) TB: <1, Negative	7
HTC_TST_TA	Service Delivery Point (Facility) TB: 1-9, Negative	21
HTC_TST_TA	Service Delivery Point (Facility) TB: 1-9, Positive	5



HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Female, Negative	211
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Female, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Male, Negative	228
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Male, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Negative	400
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Positive	80
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Male, Negative	177
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Male, Positive	24
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Negative	775
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Positive	151
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Negative	376
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Positive	63
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Female, Negative	248
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Female, Positive	43
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Male, Negative	560
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Male, Positive	106
HTC_TST_TA	Service Delivery Point (Facility) Index: <1, Negative	54
HTC_TST_TA	Service Delivery Point (Facility) Index: 1-9, Negative	174



HTC_TST_TA	Service Delivery Point (Facility) ANC: 10-14, Negative	60
HTC_TST_TA	Service Delivery Point (Facility) ANC: 15-19, Negative	5,877
HTC_TST_TA	Service Delivery Point (Facility) ANC: 15-19, Positive	158
HTC_TST_TA	Service Delivery Point (Facility) ANC: 20-24, Negative	5,877
HTC_TST_TA	Service Delivery Point (Facility) ANC: 20-24, Positive	355
HTC_TST_TA	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	1,147
HTC_TST_TA	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	9
HTC_TST_TA	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	1,220
HTC_TST_TA	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	10
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	1,033
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	78
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	403
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	11
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	1,838
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	120
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	795
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	35
HTC_TST_TA	Service Delivery Point (Facility) VCT: 50+, Female, Negative	637
HTC_TST_TA	Service Delivery Point (Facility) VCT: 50+, Female, Positive	35
HTC_TST_TA	Service Delivery Point (Facility) VCT: 50+, Male,	1,168



	Negative	
HTC_TST_TA	Service Delivery Point (Facility) VCT: 50+, Male, Positive	60
HTC_TST_TA	Service Delivery Point (Facility) VCT: <1, Negative	294
HTC_TST_TA	Service Delivery Point (Facility) VCT: <1, Positive	3
HTC_TST_TA	Service Delivery Point (Facility) VCT: 1-9, Negative	919
HTC_TST_TA	Service Delivery Point (Facility) VCT: 1-9, Positive	7
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Female, Negative	974
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Female, Positive	221
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Male, Negative	590
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Male, Positive	100
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Female, Negative	1,088
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Female, Positive	223
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Male, Negative	629
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Male, Positive	207
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Female, Negative	873
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Female, Positive	166
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Male, Negative	630
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Male, Positive	138
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Female, Negative	533
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49,	151

	Female, Positive	
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Male, Negative	648
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Male, Positive	125
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Female, Negative	7,335
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Female, Positive	526
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Male, Negative	3,924
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Male, Positive	277
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Female, Negative	8,149
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Female, Positive	583
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Male, Negative	4,917
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Male, Positive	358
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Female, Negative	6,230
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Female, Positive	452
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Male, Negative	4,475
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Male, Positive	321
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Female, Negative	3,730
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Female, Positive	264
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Male,	3,769



	Negative	
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Male, Positive	266
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Female, Negative	29,924
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Female, Positive	1,687
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Male, Negative	16,017
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Male, Positive	902
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Female, Negative	33,248
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Female, Positive	1,879
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Male, Negative	20,076
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Male, Positive	1,132
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Female, Negative	25,424
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Female, Positive	1,438
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Male, Negative	18,280
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Male, Positive	1,024
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Female, Negative	15,230
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Female, Positive	864
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Male, Negative	15,377
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Male, Positive	868



	Male, Positive	
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 25-29, Female, Negative	12,676
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 25-29, Female, Positive	351
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 30-34, Female, Negative	8,249
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 30-34, Female, Positive	229
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 35-39, Female, Negative	3,059
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 35-39, Female, Positive	82
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 40-49, Female, Negative	649
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 40-49, Female, Positive	6
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Female, Negative	171
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Female, Positive	41
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Male, Negative	106
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Male, Positive	34
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Female, Negative	204
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Female, Positive	54
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Male, Negative	115
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Male, Positive	29
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39,	149



	Female, Negative	
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Female, Positive	43
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Male, Negative	107
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Male, Positive	26
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Female, Negative	84
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Female, Positive	20
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Male, Negative	89
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Male, Positive	28
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 25-29, Female, Negative	2,494
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 25-29, Female, Positive	143
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 25-29, Male, Negative	1,364
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 25-29, Male, Positive	75
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 30-34, Female, Negative	2,771
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 30-34, Female, Positive	160
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 30-34, Male, Negative	1,676
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 30-34, Male, Positive	80
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 35-39, Female, Negative	2,116
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 35-39, Female, Positive	101



	Female, Positive	
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 35-39, Male, Negative	1,523
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 35-39, Male, Positive	84
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 40-49, Female, Negative	1,270
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 40-49, Female, Positive	73
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 40-49, Male, Negative	1,283
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 40-49, Male, Positive	62
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	2,764
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	2,793
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	38
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	38
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,526
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,191
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	84
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with	1,562



	documented HIV status, during the reporting period)	
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	44
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,074
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,013
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	462
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	551
PMTCT_EID_TA	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	2,576
PMTCT_EID_TA	By infants who received a virologic test within 2 months of birth	2,058
PMTCT_EID_TA	By infants who received their first virologic HIV test between 2 and 12 months of age	518
PMTCT_EID_TA	Sum of Infant Age disaggregates	2,576
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	80,867
TX_CURR_TA	Age/Sex: 15-19 Male	355
TX_CURR_TA	Age/Sex: 15-19 Female	935
TX_CURR_TA	Sum of Age/Sex disaggregations	1,290
TX_CURR_TA	Age/Sex: <1	218
TX_CURR_TA	Age/Sex: 1-9	1,827
TX_CURR_TA	Age/Sex: 10-14 Male	2,228
TX_CURR_TA	Age/Sex: 10-14 Female	2,509



TX_CURR_TA	Age/Sex: 20-24 Male	705
TX_CURR_TA	Age/Sex: 50+ Male	5,371
TX_CURR_TA	Age/Sex: 20-24 Female	3,444
TX_CURR_TA	Age/Sex: 50+ Female	8,880
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 25-29, Female, Positive	6,375
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 25-29, Male, Positive	1,451
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 30-34, Female, Positive	9,137
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 30-34, Male, Positive	2,530
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 35-39, Female, Positive	9,653
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive	3,406
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 40-49, Female, Positive	14,312
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 40-49, Male, Positive	7,531
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	22,082
TX_NEW_TA	By Age/Sex: <1	25
TX_NEW_TA	By Age/Sex: 1-9	98
TX_NEW_TA	By Age/Sex: 10-14 Male	122
TX_NEW_TA	By Age/Sex: 15-19 Male	480
TX_NEW_TA	By Age/Sex: 20-24 Male	842
TX_NEW_TA	By Age/Sex: 50+ Male	1,342
TX_NEW_TA	By Age/Sex: 10-14 Female	132
TX_NEW_TA	By Age/Sex: 15-19 Female	1,082
TX_NEW_TA	By Age/Sex: 20-24 Female	1,931
TX_NEW_TA	By Age/Sex: 50+ Female	672
TX_NEW_TA	Sum of Age/Sex disaggregates	6,603



TX_NEW_TA	Pregnancy status	6,620
TX_NEW_TA	Breastfeeding status	356
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Female, Positive	2,762
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Male, Positive	1,404
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Female, Positive	2,983
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Male, Positive	1,734
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Female, Positive	2,193
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive	1,582
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Female, Positive	1,320
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Male, Positive	1,378
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	38,631
TX_PVLS_TA	Denominator: Indication: Routine	34,781
TX_PVLS_TA	Denominator: Indication: Targeted	3,850
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	381
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	381
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	381
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	381
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	16,999
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+	1,539



	Female Targeted	
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	16,999
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	1,539
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	17,586
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	19,545
TX_RET_TA	Numerator by Status: Breastfeeding	1,047
TX_RET_TA	Denominator by Status: Breastfeeding	1,168
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	475
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6,556
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	712
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	9,843
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	531
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	7,354



TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	789
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	10,871
TX_TB_TA	Number of ART patients who were screened for TB at least once during the reporting period	64,496
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Female	1,366
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Male	1,644
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Female	44,424
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Male	17,062
TX_TB_TA	Denominator: By Specimen Sent: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	402
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	306
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	96
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	45,111
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	3,238
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	12,902
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	3,245

Implementing Mechanism Details

Mechanism ID: 18229	Mechanism Name: Strengthening the Capacity of the National AIDS Control Committee
----------------------------	--



Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: NACC	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 1,199,851	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,199,851	
Funding Source	Funding Amount
GHP-State	1,199,851

Cross-Cutting Budget Attribution(s)

Human Resources for Health	783,461
----------------------------	---------

Budget Code Information

Mechanism ID:	18229	
Mechanism Name:	Strengthening the Capacity of the National AIDS Control Committee	
Prime Partner Name:	NACC	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0



Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	68,560
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	617,040
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount



Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	514,251
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	196
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	68
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	128

Implementing Mechanism Details

Mechanism ID: 18230	Mechanism Name: Strengthening Public Health Laboratory Systems in Cameroon
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Global Health Systems Solutions	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No



Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 1,162,853	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,162,853	
Funding Source	Funding Amount
GHP-State	1,162,853

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 18230		
Mechanism Name: Strengthening Public Health Laboratory Systems in Cameroon		
Prime Partner Name: Global Health Systems Solutions		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount



Governance and Systems	HLAB	1,162,853
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0



Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18667	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 70028	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 70029	Mechanism Name: [Placeholder - 70029 Cameroon HHS/CDC]
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: World Health Organization	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	



Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 70029		
Mechanism Name: [Placeholder - 70029 Cameroon HHS/CDC]		
Prime Partner Name: World Health Organization		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0



Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	25,000
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0



Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 70030	Mechanism Name: [Placeholder - 70030 Cameroon HHS/CDC]
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: UNICEF	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

Human Resources for Health	92,953
----------------------------	--------

Budget Code Information

Mechanism ID:	70030	
Mechanism Name:	[Placeholder - 70030 Cameroon HHS/CDC]	
Prime Partner Name:	UNICEF	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount



Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0



Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	46,476
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	46,477

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 70031	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 70032	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 70035	TBD: Yes
REDACTED	



Implementing Mechanism Details

Mechanism ID: 70036	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 70037	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 80015	Mechanism Name: GHSC - Rapid Test Kit (GHSC-RTK)
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Remote Medical International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 80015		
Mechanism Name: GHSC - Rapid Test Kit (GHSC-RTK)		
Prime Partner Name: Remote Medical International		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount



Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	128,000
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 80016	Mechanism Name: GHSC-TA Central Task Order
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Chemonics International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes

Approved



Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

Human Resources for Health	260,000
Motor Vehicles: Leased	20,000

Budget Code Information

Mechanism ID: 80016		
Mechanism Name: GHSC-TA Central Task Order		
Prime Partner Name: Chemonics International		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount



Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	678,714
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0



Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 80023	Mechanism Name: UCSF - HMIS
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of California at San Francisco	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 80023



Mechanism Name: UCSF - HMIS		
Prime Partner Name: University of California at San Francisco		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0



Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 80042	TBD: Yes
REDACTED	



Agency Information - Costs of Doing Business
U.S. Agency for International Development

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Computers/IT Services		11,375		11,375	0	11,375
ICASS		386,128		386,128	0	386,128
Indirect Costs		83,352		83,352	0	83,352
Management Meetings/Professional Development		61,502		61,502	0	61,502
Non-ICASS Administrative Costs		88,972	300,122	389,094	0	389,094
Staff Program Travel		116,858	0	116,858	0	116,858
USG Staff Salaries and Benefits - Internationally Recruited		227,627	0	227,627	0	227,627
USG Staff Salaries and Benefits - Locally Recruited		202,599	0	202,599	0	202,599
Total	0	1,178,413	300,122	1,478,535	0	1,478,535



U.S. Department of Defense

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Computers/IT Services		5,000		5,000	0	5,000
ICASS		20,000		20,000	0	20,000
Indirect Costs		12,000		12,000	0	12,000
Management Meetings/Professional Development		10,000		10,000	0	10,000
Non-ICASS Administrative Costs		10,000		10,000	0	10,000
Staff Program Travel		30,000		30,000	0	30,000
USG Staff Salaries and Benefits - Locally Recruited		150,000		150,000	0	150,000
Total	0	237,000	0	237,000	0	237,000

U.S. Department of Health and Human Services/Centers for Disease Control and Prevention

Agency Cost	GAP	GHP-State	GHP-USAID	Funding	Applied	Total All
-------------	-----	-----------	-----------	---------	---------	-----------



of Doing Business				Source Total	Pipeline	Funding Sources and Applied Pipeline Amount
Capital Security Cost Sharing		134,490		134,490	0	134,490
Computers/IT Services		239,239		239,239	0	239,239
ICASS		1,233,585		1,233,585	0	1,233,585
Institutional Contractors	0	100,000		100,000	0	100,000
Management Meetings/Professional Development		40,000		40,000	0	40,000
Non-ICASS Administrative Costs		196,393		196,393	0	196,393
Staff Program Travel	0	680,184		680,184	0	680,184
USG Staff Salaries and Benefits - Internationally Recruited				0	0	0
USG Staff Salaries and Benefits - Locally Recruited	575,119	1,621,627		2,196,746	0	2,196,746
Total	575,119	4,245,518	0	4,820,637	0	4,820,637



U.S. Department of State

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Computers/IT Services		3,000		3,000	0	3,000
ICASS		25,653		25,653	174,347	200,000
Management Meetings/Professional Development		15,000		15,000	0	15,000
Staff Program Travel		30,000		30,000	0	30,000
USG Staff Salaries and Benefits - Internationally Recruited				0	360,000	360,000
USG Staff Salaries and Benefits - Locally Recruited		42,000		42,000	0	42,000
Total	0	115,653	0	115,653	534,347	650,000

U.S. Peace Corps

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied
-------------------------------	-----	-----------	-----------	----------------------	------------------	---------------------------------------

Approved



						Pipeline Amount
Non-ICASS Administrative Costs		0		0	177,310	177,310
Peace Corps Volunteer Costs				0	332,140	332,140
Staff Program Travel		0		0	31,257	31,257
USG Staff Salaries and Benefits - Locally Recruited		0		0	91,375	91,375
Total	0	0	0	0	632,082	632,082